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1.1 Topical Drug Delivery 
Controlled drug delivery is a concept based on Paul Ehrlich’s Idea of the magic bullet. 
It deals with the effect of a drug only in the way it is intended without any side effect.[1] 
In the more than 100 years that have passed since the conception of this hypothesis, 
much research has been conducted towards its realization.  
Side effects often come into play when a drug, for instance, binds to a different 
receptor in an unspecific manner. This usually happens, when the drug’s concentration 
in the target tissue is too high or the drug enters a tissue with other potential binders 
being present. Increasing the specificity to the target receptor by chemical modification 
is one way to solve this problem, but it has its limits. Another way is to use 
nanomedicine. It helps to increase the drug’s effectiveness, for example, by gaining 
control over the spatial distribution or by an improved control over the concentration in 
the target tissue. There is a minimum required concentration for an effect to occur and 
an upper limit, which marks the onset of toxic effects, caused by, e.g., non-specific 
binding (See Figure 1).  
 
Figure 1. The drug concentration in the blood over the course of a medical treatment. By the administration of a 
small molecular drug (black curve), many dosages are needed and blood concentration varies strongly, even below 
and above the therapeutic window. Using the controlled release from a nanomedicine, the drug concentration is 






The interval in between is called the therapeutic window and marks the effective range 
of concentration for a drug. Especially for cytotoxic anti-cancer drugs the therapeutic 
window can be very narrow.[3] 
1.2 Nanomedicines 
The task of nanomedicines is to gain control over the drug’s distribution over the body 
in a temporal manner. This means on one hand to direct the drug to the site of 
pharmacological need, and on the other hand to maintain the drug’s concentration 
within the therapeutic window. Examples for nanomedicines are antibody-based 
systems like antibody-drug conjugates (ADC),[4] or synthetic systems like micelles, 
liposomes, polymeric micelles, and polymer beads. All these systems are loaded with 
a drug either via covalent attachment or by physical entrapment. Depending on their 
properties, they can provide passive or active targeting, triggered release and 
protection from premature clearance, which is a common problem of low-molecular 
weight drugs. This can be prevented by the attachment of the drug to a nanoscale 
DDS with a molecular weight (MW) of > 30 kDa, which marks the limit for the renal 
excretion.[5] 
 
Figure 2. Visualization of Ringsdorf’s model of a pharmacologically active polymer, adapted from ref. [3] 
The concept, which first included these ideas and involved polymers for their 
realization, is Ringsdorf’s model of the pharmacologically active polymer (see Figure 
2).[6] In this model, a polymer was thought of as a modular platform that can provide 
certain properties to form a pharmacologically active architecture. In this concept, an 
active targeting unit (e.g. an antibody) can be attached to a partly hydrophilic block-
copolymer which is bound to a hydrophobic drug through a cleavable linker. The 
hydrophilic block provides the necessary water solubility to an otherwise insoluble 





directs the polymer to its destination. Once the target is reached, the linker is cleaved 
and the released drug becomes active. 
Along with the active targeting, which involves a specific binding, there is a second 
form, the passive targeting. A key mechanism of passive targeting is enhanced 
permeation and retention (EPR) effect which was first described by Maeda and 
coworkers in 1986.[7] It is based on the special condition of tumorous and inflamed 
tissue. Because of irregular growth of cells, the vasculatory system is more permeable 
for macromolecules and the tumor tissue fenestrated.[8] Macromolecules such as 
nanoscopic DDS are able to transcend into the target tissue. As lymphatic drainage is 
impaired in these types of tissues the macromolecules are retained and their cargo is 
more likely to be released. Additionally, tumor growth and inflammations are 
accompanied with low pH in the tissue. This condition can be used for a pH-dependent 
release (see chapter 1.4).  
 
Figure 3. Schematic description of the EPR effect. Normal tissue (top) is not penetrated by macromolecules. 
Alterations in the structure of tumorous tissue lead to increased penetration of nanoscopic DDS and higher length 
of stay due to the lack of lymphatic drainage. Reproduced with permission from John Wiley and Sons.[9] 
Based on the EPR effect, more sophisticated mechanisms of action have been 
developed. The super enhanced permeation and retention effect (SUPR) is a two-step 
procedure and involves an antibody (Ab)-bound photosensitizer.[10] In a first step, this 
ADC is injected intravenously and locates in the tumor tissue due to the specific 
binding of the Ab. Upon the irradiation of light, singlet oxygen is generated locally, 
which leads to the immediate necrotic cell death without harming the nearby normal 
tissue. Due to the tissue damage, the perfusion of the tumorous tissue is strongly 






1.3 Classes of Nanomedicines 
There are many types of nanomedicines of which can be subdivided into two classes. 
Polymer therapeutics describe all types of nanosized polymer-drug conjugates at 
which a small drug or protein is bound to a polymer covalently.[11]  In contrast to that 
a Drug delivery system is an architecture that physically entraps the drug without a 
covalent linkage. 
 
Figure 4. Structural variety of polymeric nanomedicines. Modified from [12]. 
1.1.1 Polymer therapeutics  
The most typical way to alter a drug’s or protein’s properties is by conjugation with 
poly(ethylene-glycol) (PEG), N-(2-hydroxypropyl)methacrylamide (HPMA), or 
polyglutamate with typical molecular weights of 5 kDa to 40 kDa.[13] This leads to 





shielding from recognition by the immune-system. In the case of conjugated small 
drug, the molecular weight is increased by one or several orders of magnitude to the 
range of the EPR effect. This strategy has been employed to a multitude of drugs and 
proteins, of which > 10 have entered the market and > 10 more are in clinical trials.[11] 
For example, Oncaspar, a PEGylated asparaginase was introduced into the market in 
1994.[14] L-asparagine is a non-essential amino acid, which can be produced by 
normal cells, but not by cancer cells and thus has to be taken up from the blood stream. 
Oncaspar catalyzes the hydrolysis of asparagine and thus deprives the cancerous 
tissue of its asparagine source which slows down tumor growth. ProLindac is a 
platinum-based anti-cancer drug bound to a HMPA backbone via a pH-degradable 
linker.[15] Based on the EPR-effect, the conjugate accumulates in the tumor tissue, 
where the cis-platinum is released and thereby its cytotoxic effect activated.  
1.1.2 Liposomes 
Another big group of nanomedicines currently used in practice is made up by liposomal 
formulations.[16] Liposomes are lamellar vesicles with usually 50 to 150 nm in 
diameter that comprise an aqueous volume surrounded by a phospholipid bilayer.[17] 
The phospholipids typically used are amphiphilic molecules with fatty acids as 
lipophilic tails and a zwitterionic hydrophilic head group. While small unilamellar 
vesicles (SUV, 25 - 100 nm) and large unilamellar vesicles (LUV, 100 - 500 nm) 
possess only a single phospholipid bilayer as a membrane, multi-lamellar vesicles 
(MLV, 200 – 1000 nm) exhibit several ones. Verteporfin, for instance, is an injectable 
liposomal formulation of a porphyrin-type photosensitizer (PS) for the treatment of age-
related macular degeneration (AMD). [18–20] In the more severe, so-called wet form 
of AMD, the macula is neovascularized. The newly formed, abnormal blood vessels 
are leaky and damage the surrounding tissue. The application of Verteporfin involves 
two steps. First, an enrichment of PS in the target tissue due to the nanoformulation 
takes place, which is the first way to limit the effect locally. Then, again locally, the 
macula is irradiated with red laser light to induce the generation of singlet oxygen and 
the subsequent damage to the endothelial cells. Platelet adhesion then leads to an 
occlusion of the abnormal blood vessels and stops the leakage. 
Nanoliposomally formulated doxorubicin (Doxil) poses an example of a more complex 
design.[21,22] Doxorubicin is loaded into vesicles that bear PEG chains grafted onto 





intravenously and the liposomes, protected from the immunorecognition by the PEG-
layer accumulate in the target tissue where it is released. 
 
Figure 5. Structure of the liposomal formulation of DOX, doxil. Reproduced with permission from Elsevier.[22] 
1.1.3 Polymeric micelles 
Polymeric micelles are the polymeric analogs of small-molecular micelles. They self-
assemble out of single polymeric molecules that form bigger structures driven by 
hydrophobic interactions.[23] In the same way they possess a hydrophobic part that 
forms the core, where lipophilic drugs can be solubilized, as well as one or two 
hydrophilic parts which assemble into the hydrophilic shell. The formation of the 
micellar structure is a concentration-dependent process, which means that a constant 
dynamic exchange of polymer chains takes place and dilution will lead to the 
disassembly. The micellar stability is expressed by the critical micellar concentration 
(CMC), the minimum concentration above which association to micelles takes place. 
The combination of materials used in this type of architecture also has a strong 
influence on its stability. As hydrophilic block, PEG is a commonly used material, 
because of its water solubility and its good biocompatibility. Still, some studies 
indicated the limitations of PEG, pointing out the accelerated blood clearance (ABC) 
phenomenon.[24,25] It describes the faster clearance of PEG-based micelles from the 
blood stream at the administration of the second dose in an IgM-mediated manner and 
indicates at least some immunogenicity of PEG. Other hydrophilic polymers used for 
polymeric micelles include poly(N-vinylpyrrolidone) (PVP) and the polyzwitterionic 
polybetaines. PVP has similar properties to PEG, it’s biocompatible and hydrophilic, 
but is not as good in terms of resisting protein adsorption.[26] However, it has proven 





As polymeric materials for the hydrophobic block biodegradable polyesters are 
commonly used. These include poly(lactic acid) (PLA),[28] poly(lactide-co-glycolide) 
(PLGA),[29] and poly(caprolactone) (PCL).[30] The usage of degradable materials 
ensures the complete degradation and prevents accumulation in the body. 
Even though they’re much more stable than their small-molecular counterparts (CMC 
106-107 M, vs. 103-104 M),[31] polymeric micelles still undergo disassembly when 
diluted in a large volume, e.g. during i.v. injection. To overcome this problem, common 
attempts were made to crosslink the micelle in the hydrophobic core with cleavable 
linkages to maintain biodegradability and achieve a triggered release.[32] 
In addition to the two blocks, further functionalization is possible and building blocks 
can be used for multiple purposes. In a recent example by Low et al., oligoaspartic 
acid was used as the hydrophilic block and targeting unit at the same time. At the 
hydrophobic terminus, doxorubicin, which contributed to the hydrophobic interactions, 
was attached covalently via a hydrazone bond, to provide a pH-dependent release 
(see Figure 6). [33] 
 
Figure 6. Structure of the polymeric chain and release principle of the polymeric micelles presented by Low et al. 
adapted from ACS ref. [33]. This is an unofficial adaptation of an article that appeared in an ACS publication. ACS 
has not endorsed the content of this adaptation or the context of its use. 
1.1.4 Dendritic polymers 
Dendrimers are polymers with globular shape and many highly branched arms 
originating from a focal point.[34] Their step-wise synthesis leads to highly defined 
macromolecules with a low dispersity and a precise number of end groups. In contrast 
to that, a hyperbranched polymer has a highly branched structure a high surface 
functionality, but also contains linear units. While dendrimers are identical molecules, 
hyperbranched polymers vary in MW and even two molecules with equal mass are 
most probably constitutional isomers. Thus, hyperbranched polymers are closely 





The combination of linear and dendritic polymers yields a plethora of structural 
possibilities.[35] These include linear-dendritic hybrids, a dendrimer functionalized 
with a linear chain at the center, multi-arm star polymers, a hyperbranched polymer 
decorated with linear chains, and dendrigrafts as well as hypergrafted polymers, linear 
chains to which either dendrimers or hyperbranched polymers are attached (see 
Figure 7). 
 
Figure 7. Different dendritic polymeric architectures. For more information see text. Reproduced with permission 
from Elsevier.[35] 
1.1.4.1 Dendrimers 
Dendrimers first emerged in the 1980’s, when they were theoretically described by 
DeGennes after which Tomalia et al. realized the synthesis of the first example, the 
poly(amido amine) (PAMAM) dendrimer (see Figure 9).[36,37] Since then this new 
class of polymers has been explored with many other building blocks and different 
routes of synthesis. As full branching was the goal, usually ABX-type monomers were 
used. (where X = 2,3,…) While in the divergent route the synthesis is started at the 
focal point and from then on, all peripheral groups are functionalized with another 
monomer, to form the next higher generation of a dendrimer,[36] in the convergent 
route this direction is inverted.[38] Here, the synthesis is started from the end groups 
and is completed by the attachment to the focal point. As in both types of synthetic 





bind exactly one additional monomer. This is typically done via the usage of either a 
protective group, or two chemically orthogonal reactions.[39]  
The materials used to construct this type of polymers include hydrophobic 
polyarylethers,[38] dendritic PEG-analogs,[40] and polyester-based dendrimers (e.g. 
Boltorn H30, see Figure 9) have been synthesized and while in the early years,[41] 
the main focus lay on dendrimer chemistry, it has shifted more and more towards 
biomedical applications. Like their linear counterparts, dendrimers bear numerous 
functional groups, but there are many structural differences. Linear polymers are often 
more polydisperse and arrange in a random coil structure. In contrast to that, 
dendrimers are more globular, and their physiochemical properties often differ 
between their inner, often hydrophobic part and their surface, where many of the 
functional groups are located. These characteristics can be exploited for numerous 
biomedical applications.[42]  An application for a lysin-based, surface-functionalized 
dendrimer as a microbicide against HIV and HSV is SPL 7013 (marketed as 
VivaGel®).[43,44] Its polyanionic surface allows one to bind to the surface of a virus 
by multivalent interactions and thereby prevents an infection. It is an example for a 
dendrimer to act as a drug itself, but it can also be used as a drug container. The 
reported dendritic box by the Meijer group was one of the first examples for this type 
of use.[45]  The authors describe a G5 poly(propylene imine) dendrimer whose surface 
was decorated with Boc-protected phenylalanine in the presence and absence of 
various guest molecules (see Figure 8A). While for low-generation dendrimers, the 
guest molecules could still diffuse out of the container, the steric hindrance of the 
peripheral functionalization in the case of the high generation dendrimers was too high 
for the guest to leave the dendritic box. The authors also showed selective release 
after the co-encapsulation of two differently sized guest molecules. By cleaving off the 
Boc-protecting group, the smaller guest was released, while the removal of the amino 
acid was necessary to also free bigger guest (see Figure 8B).[46] 
The dendrimer’s interior can also as a hydrophobic pocket to bind an unpolar drug via 
hydrophobic interactions and a hydrophilic surface to increase water solubility.[47] For 
example, the solubility of a set of non-steroidal anti-inflammatory drugs (NSAIDs) 
could be improved by the encapsulation into PAMAM. In this study, not only 
hydrophobic interactions played a role, but also hydrogen bonding between the 






Figure 8. (A) Chemical structure of the "dendritic box" by de Meijer and co-workers. (B) Co-encapsulation of two 
differently sized guest molecules with subsequent selective release after deprotection and removal of the amino 
acid.  [45,46] 
Dendrimers with a hydrophobic interior and hydrophilic surface groups are generally 
not efficient carriers, because of their low water solubility. Additionally, polycations, 
such as polyamines usually have the problem of increased toxicity due to adherence 
to the negatively charged cellular membrane. To circumvent these problems, many 
dendrimers are PEGylated, forming a core-shell particle with a hydrophobic interior 
and a hydrophilic exterior, a unimolecular micelle (see section 1.1.6). 
1.1.4.2 Hyperbranched polymers 
Although dendrimers exhibit a perfectly branched structure and well defined molecular 
properties, their major drawback is their tedious synthesis. Hyperbranched polymers 
are far more accessible, because they can be produced in a one-step approach. 
Hyperbranched polymers are not perfectly branched but exhibit a certain percentage 
of linear monomeric units in their interior. The degree of branching is an important 
value to describe the character of a certain dendritic polymer as rather dendritic or 
linear. Unlike their fully branched counterparts, hyperbranched polymers are not 
limited to a certain generation and size, respectively. First examples have already 
been synthesized in the 19th century,[48] first theoretic description was done by Flory 






Many synthetic strategies have been developed involving either a single AB2-type 
monomer or two different (typically A2 and B3) monomers.[35] 
 
Figure 9. Chemical structure of different dendrimers (A,B) and hyperbranched polymers (C,D). (A) Boltorn H30, (B) 
poly(amido amine) G3, (C) hyperbranched polyglycerol, (D) poly(ethylene imine). 
Due to their characteristics, hyperbranched polymers have been explored for a 
multitude of biomedical applications. A water-soluble hyperbranched polyhydroxyl 
polymer (HBPH) was used for the encapsulation of apoptosis-initiating cytochrome C 
and a near-IR dye.[50] The additional covalent attachment of folic acid ligands yielded 
theranostic nanoparticles for the passive and active targeting of folate receptor-
positive cancer cells. Poly(ethylene imine) (PEI, see Figure 9) is a hyperbranched 
polyamine, that, among other applications, is used in gene transfection.[51,52] PEI of 
the molecular weight of 50 kDa and 800 kDa was employed as a DNA-carrier. The 
interaction of DNA and PEI is based on ionic interactions between the anionic poly 
sugar-phosphate backbone and the polycation PEI. In addition to that, the “proton-





significantly. It describes the role of PEI as a polymer that binds protons due to its 
manifold amine groups and acts as a pH buffer. The results are first of all that 
transfected DNA is not degraded in the relatively mild environment and secondly that 
lysosomal swelling and rupture is the basis of the escape mechanism. Like PEI, 
hyperbranched poly(amido amine)s (HPAAs) can also be used for gene delivery. Chen 
et al. reported a cyclodextrin (CD)-decorated HPAA which could be used as a gene 
delivery vector.[53] The additional functionalization with CD increased the 
fluorescence of the material as well as could encapsulate rhodamine B as a model 
drug.  
Tolerability and toxicity was improved while keeping the transfection efficiency in the 
same range by the usage of aminated hyperbranched polyglycerol (hPG-NH2) instead 
of PEI.[52,54] Hyperbranched polyglycerol (hPG) is a polyether with few internal and 
many superficial -OH groups that provide both hydrophilicity and the possibility of 
functionalization (see Figure 9). It was shown that hPG-NH2 could bind and transfect 
DNA in a comparable manner as PEI, the major difference lay in the charge of the 
hyperbranched polymer. While PEI has additional amine groups in its interior that 
contribute to its toxicity, amino-functionalization in hPG-NH2 is only superficial, leading 
to an increased tolerability. 
hPG (see Figure 9) is a highly branched (DB typically between 0.53 and 0.59), 
hydrophilic polymer that can be produced with a low PDI (1.1 to 1.5) via an anionic 
ring-opening multibranching polymerization from glycidol and a starter molecule.[55] 
Its biocompatibility, low toxicity, and high density of functional groups have made it a 
promising and well explored material for biomedical applications.[56–59] For example, 
it was used as a water-soluble polymer backbone for the delivery of drugs and cells. 
Jeong et al. functionalized hPG with a long alkyl chain as well as vascular binding 
peptide. This construct was then used to target stem cells to inflamed tissue, via the 
alkyl chain inserting into the cellular membrane and the oligopeptide binding to 
receptors on the inflamed endothelium.[60] González-Rodríguez et al. reported a hPG-
morphine conjugate which passively targeted inflamed tissue and thus induced 
analgesia peripherally without side effects by acting on the central nervous system.[61] 
Low MW hPG can be employed in organ-preserving solutions. It was shown that the 
usage of hPG of a MW of 1 kDa was advantageous over the commonly used 





based solutions also outperformed the current gold standard, University of Wisconsin 
(UW) solution for the perfusion of organs before transplantation.[64] In this context, 
hPG was used to maintain the colloidal osmotic pressure and due to its hyperbranched 
architecture exhibited a low intrinsic viscosity compared to linear polymers, which was 
beneficial for this application. Among the vast number of applications that use hPG as 
a solubilizer, bind drugs and proteins or employ superficially functionalized hPG, 
numerous approaches exploit hPG as a building block for higher architectures, such 
as nanogels, core-shell and core-multishell architectures.[65] 
1.1.5  hPG-based nanogels 
Size is a critical issue when it comes to the fate of nanoparticles applied to the body. 
Thus gel-like, hydrophilic polymeric particles in the size range from 20 to 1000 are 
especially promising for biomedical applications.[66,67] To generate hPG particles of 
a size greater than 20 nm, different strategies were employed. Sisson et al. reported 
PG particles of a high molecular weight in a miniemulsion-based approach. hPG 
macromonomers and cross-linking agents were emulsified in a nanoreactor that 
defined the size. Alkyne/azide click chemistry was used to link the monomers and 
yielded particles of 20 to 90 nm.[68] This procedure was then improved by Steinhilber 
et al. via the introduction of the inverse nanoprecipitation.[69] This surfactant-free 
method allowed the encapsulation of an enzyme into nanogels of 100 to 1000 nm in 
size. pH-dependent degradation was realized by acid-labile acetal linkages after which 
the released enzyme was fully intact. A similar approach was used by Dimde et al. 
who synthesized a hPG/PEI-based nanogel with acetal linkages using thiol-ene click 
chemistry.[70] siRNA was encapsulated during the synthesis and the loaded particles 
were taken up by GFP-expressing HeLa cells. The cargo was released upon 
intracellular pH drop which eventually led to the successful silencing the expression of 
GFP. Although being mainly hydrophilic architectures, Giulbudagian et al. achieved 
the encapsulation of the small hydrophobic drug dexamethasone (DXM) into β-
cyclodextrin (β-CD)-functionalized thermoresponsive nanogels.[71] In their study they 
proved the binding between DXM and the β-CD via electron paramagnetic resonance 
spectroscopy and could show that the formulation into this nanogel outperformed a 






1.1.6 Dendritic core-shell and core-multishell systems 
Unimolecular micelles are single molecules and as such maintain their structure at all 
concentrations. This advantage makes them especially appealing for any applications 
that involve high dilutions, such as i.v. injections. The first example of a unimolecular 
micelle was reported in 1991 by Newkome et al.[72,73] In this approach, an aliphatic 
dendrimer with multiple peripheral carboxylate groups was synthesized in a divergent  
approach. The unloaded particles showed no aggregation and could loaded with 
several dyes to prove their capability to solubilize a hydrophobic molecule. Hawker 
and Frechét extended this principle to an electron-rich dendrimer which was 
synthesized in the convergent route.[74] Aromatic guest molecules could be loaded, 
while the system showed no CMC.  
Since then the basic design principle of a lipophilic or hydrophilic interior and a water-
soluble outer part was used to construct nanoparticles. With building blocks like 
dendrimers or hyperbranched polymers at hand, the obvious choice was to use them 
as a core and facilitate water solubility by the functionalization with a linear hydrophilic 
polymer to yield a dendric core-shell (CS) nanoparticle.[75] Particularly, PEG was 
chosen for this task because of its many advantages like its stealth effect, solubility in 
many solvents, and high biocompatibility. CS nanosystems with hydrophilic cores were 
generally used to encapsulate hydrophilic guests. For instance, a PAMAM-dendrimer 
was functionalized with PEG and folic acid for active and passive tumor targeting in a 
mouse model.[76] 5-Fluorouracil (5FU) was loaded up to 31% and the application a 
mouse tumor model led to high accumulation in the target tissue. A similar setup was 
chosen by Jin et al. who also used PAMAM and employed a mixed shell approach 
with PEG and the pH-sensitive poly(2-(N,N-diethylamino)ethyl methacrylate) 
(PDEA).[77] The nanocarriers were also loaded with 5FU and showed a pH-dependent 
release. At systemic pH (7.4), the release was significantly slower than at a pH of 6.5 






Figure 10. Illstration of the structure and release mechanism of the CS nanocarrier reported by Jin et al. The 
transporter can bo loaded wich 5FU and the additional functionalization with PDEA leads to pH dependent release. 
Reproduced with permission from Elsevier.[77] 
For the encapsulation of hydrophobic guest molecules, the core needs to be 
hydrophobic. This can either be realized by the usage of a hydrophobic dendritic 
polymer or via the introduction of hydrophobic moieties in an otherwise hydrophilic 
core. Kurniasih et al. protected selectively the terminal 1,2-diols of hPG and 
functionalized the remaining ones selectively with different hydrophobic moieties.[78] 
The type of functionalization was adapted to the designated guest molecule by the 
usage of hydrophobic, fluorous-fluorous, or aromatic interactions. By deprotection, the 
hydrophilicity of the terminal groups was restored and a dendritic CS architecture 
obtained. The authors could prove that by this approach the water solubility of the 
loaded dyes increased manifold and the encapsulation involved supramolecular 
aggregates. The same authors extended a selected architecture bearing biphenyl 
groups at the core by the functionalization of the peripheral hydroxy groups with a PEG 
shell. [79] The resulting nanocarrier could then be co-loaded with pyrene and Nile red 
with interesting release properties. While pyrene was encapsulated into the unimers 
by π-π stacking, it could only be released via the enzymatic cleavage of the moieties 
in the core. Nile red, on the other hand, was solubilized in the nanocarrier aggregates 
and was released upon dilution or under acidic conditions. 
A typical task in drug delivery is the solubilization of hydrophobic drugs with low water 
solubility. Thus, encapsulation into a core-shell architecture which a hydrophobic is 
the most promising approach. Mainly two types of polymers have been used, 
polyethylene (PE) and polyesters (PES). The first PE-based core-shell nanocarrier 





ethylene and a PEG-functionalized olefin to yield a polymer that formed a unimolecular 
core-shell structure in water and could be loaded with the dye Nile red. Another 
example is a PE-PG CS architecture reported by Popeney et al.[81] This 
nanotransporter could be loaded with hydrophobic dyes in a unimolecular fashion and 
enhance dye-uptake into A549 cells compared to an encapsulation in small molecular 
micelles. Although PE is a non-toxic material, it lacks bio-degradability, which is an 
important feature when it comes to biomedical applications. PES are commercially 
available materials and offer the possibility for biological degradation. The use of an 
AB2-monomer (in this case bis-MPA) enables the synthesis of dendritic structures. The 
Boltorn H polymers (see Figure 9) are a commercially available material based on 2,2-
bismethylolpropionic acid (bis-MPA) and were utilized for numerous approaches to 
unimolecular micelles. For example, Zeng et al. coupled PEG of various lengths 
(5 kDa and 10 kDa) to Boltorn H30 and H40 to construct CS nanocarriers. The carriers 
could then be loaded with doxorubicin (DOX) and exhibited an elevated cytotoxicity 
towards breast cancer cells compared to DOX alone. Additional functionalization of 
this setup with the bisphosphonate alendronate was reported by Chen et al.[82] The 
synthesized nanocarriers could also be loaded with DOX and showed binding to 
hydroxyapatite, which renders them promising candidates for the treatment of bone 
cancer. 
1.1.6.1 Core-multishell (CMS) Nanocarriers 
While core-shell nanoparticles mimic the structure of a micelle, the core multishell 
nanocarrier is inspired by the liposome (see Figure 11). In a unimolecular fashion, a 
hydrophilic dendritic polymer is surrounded by a lipophilic inner shell and a hydrophilic 
outer shell. The first report of this architecture was in 2007 by Radowski et al. who 
used a PEI core for the attachment of an amphiphilic double shell consisting of an 
aliphatic diacid and mPEG.[83] This universal CMS nanotransporter could transport 
both hydrophobic and hydrophilic guests in aqueous and organic media in an 
aggregation-based mechanism.[84] Depending on the guest molecule the 
nanocarriers exhibited a critical aggregation concentration (CAC). This is the minimum 
concentration above which the CMS nanocarriers aggregated supramolecularly and 
could transport hydrophobic dyes. The authors also showed that an 
indotricarbocyanine (ITCC)-loaded CMS-nanotransporters accumulated in an F9 





could be liberated in an enzymatic degradation, the core material was exchanged for 
hPG without change in the architecture.[85,86] Because of their versatility and 
biocompatibility, the CMS nanocarriers were explored regarding their drug-loading 
properties, aggregation phenomena, and biological applicability. Fleige et al. reported 
that not only the nanocarriers aggregate to form clusters in the size range of 100-
200 nm, but also the loaded guest molecules can stack within those clusters.[86] Nile 
red, which was known to not aggregate, formed non-emissive H-stacks in this special 
nanoenvironment. SANS measurements confirmed the supramolecular nanoparticle 
aggregation but found a diameter of only 20 nm. Hydrophobic patches on the surface 
of the individual particles were identified as responsible for this effect.[87] 
Furthermore, the localization of the dye molecules within the aggregates was studied 
by UV/Vis spectroscopy,[86] fluorescence lifetime imaging (FLIM) and by a simplified 
theoretical model.[88,89] Not only small molecules can be transported by CMS-
nanotransporters, but also other nanoparticles and metal ions. Pt-nanoparticles could 
be stabilized in a methanolic solution and could still catalyze a hydrogenation 
reaction.[90] For the loading of ions, a structurally altered CMS nanotransporter, which 
contained tertiary amines in the inner shell, was designed.[91]  It was used to transport 
copper ions and release them in a pH dependent manner.  
 
Figure 11. Schematic structure of the liposome compared to the CMS architecture. Reproduced with permission 





Along with hPG and PEI, this parent architecture can be used with other dendritic 
polymers as a core. PES-based hyperbranched structures are especially promising if 
they are combined with polymeric shell arms, because they can be fully degraded. The 
combination of Boltorn H40, poly(lactic acid) (PLA), and PEG was used in several 
studies to construct CMS nanocarriers. Prabaharan et al. showed that their system 
was biocompatible and biodegradable and could be loaded with 5FU.[92] In a second 
study they additionally functionalized their system with folic acid. DOX-loaded particles 
were taken up by 4T1 mouse mammary carcinoma cells more rapidly when 
functionalized than without functionalization.[93] In a similar approach, Xu et al. utilized 
the same setup functionalized with an aptamer as a targeting ligand for the prostate-
specific membrane antigen which is expressed in cancer cells. They found increased 
amounts of DOX when loaded into the targeted nanocarriers in comparison to 
untargeted ones in vitro as well as in vivo.[94] 
1.4 Stimuli-Responsiveness 
Many of the presented nanocarrier architectures can actively and passively target the 
desired tissue in a selective way. To gain even more or less control over the spatial 
and temporal distribution, stimuli responsive systems are used. Their main working 
principle is the triggered release which means not only site-specificity regarding the 
accumulation of particles, but also their release.[95] The release is facilitated by two 
major strategies (see Figure 12). The first one involves the introduction of a cleavable 
linker between the carrier molecule and the drug, forming a prodrug. Upon a certain 
stimulus, this bond is broken, and the bioactive agent liberated. In the second 
mechanism, the carrier reacts to a stimulus with a change in the carrier structure, e.g., 
by supramolecular aggregation, charging/discharging of functional groups, or even 
decomposition.  
There is a multitude of stimuli that were used as a trigger for the release from 
nanocarriers that can be subdivided into two categories. Internal triggers are triggers 
that make use of certain conditions in the body that only exist in a confined space or 
undergo a change from one point in the body to another, e.g., from blood to a tumor 
or an inflammation. These include pH, enzymes, temperature, and redox potential. 
The second category, external stimuli offer an even more precise control over not only 
the spatial, but also the temporal distribution of a drug. They can be switched on and 





compliance. These external stimuli include, among others, light, magnetic field, and 
ultrasound. 
 
Figure 12. The two major strategies to facilitate triggered release. For details see text. Reproduced with permission 
from Elsevier.[95] 
Redox potential changes from the rather oxidative extracellular space to the 
intracellular one in relation to the glutathione/glutathione disulfide (GSH/GSSG) 
concentration.[96] This redox potential difference can be used to cleave a redox-active 
bond, for instance, a disulfide bridge site-specifically. The change from the 
extracellular to the intracellular space is especially interesting for gene delivery, 
because the genetic material needs to be protected outside and should be liberated 
as soon as it reaches the intracellular space. Carlisle et al. complexed plasmid DNA 
with thiol-containing PEI which was further crosslinked via thiol or maleimide chemistry 
to form reducible disulfide or stable thioether bonds.[97] In the subsequent in vitro 
study, the cleavable complexes outperformed the stable ones with regard to their 
transfection efficiency. Another approach of a reducible polymeric micelle was 
reported by Liu et al.[98] In their approach, Boltorn H40 was coupled to a linear 
amphiphilic polymer chain consisting of PLA connected to hydrophilic polyphosphate 
through a disulfide bridge. Furthermore, the supramolecular encapsulation of DOX 
with this amphiphile showed significantly increased release in vitro under reductive 
conditions. These results could be confirmed on HeLa cells when treated with 
glutathione monoethyl ester. 
There are many pH-gradients known in the human body. The most exploited one for 





pH values are present as well as slightly basic ones (pH 2 – pH 8).[99] In skin, the pH 
gradient starts on the surface (the so-called acid mantle) at a pH around 5 and 
approximates the systemic 7.4 in deeper skin layers.[100] In pathological states, the 
pH value can deviate. In cancerous tissue the pH value is decreased to pH 6 and 
below,[101] similar values can be measured in inflamed tissue.[102] Even on a 
microscopic level, in different cell compartments, the pH value can vary significantly. 
After endosomal uptake, the newly formed vesicle is acidified, leading to low pH values 
in the early endosome (pH 5-6), and even lower ones in the late endosome 
(pH 4-5).[103] Depending on the application, these gradients can be used for a tissue-
specific release. Li et al. reported a polymeric micelle to deliver a platinum-based anti-
cancer agent into tumors.[104] A platinum compound was coupled to a PAMAM 
dendrimer to which amphiphilic chains was attached. While the hydrophilic part 
consisted of PEG, the hydrophobic part contained tertiary amine groups, which could 
be protonated. At neutral pH, the amphiphiles assembled into a supramolecular 
aggregate, that could passively target tumor tissue because of the EPR effect. Upon 
pH change (e.g., by entering the target tissue) the tertiary amine groups were 
protonated and the aggregate disassembled due to coulomb repulsion. Interestingly, 
this type of architecture showed a very sharp transition from the assembled to the 
disassembled state within a change of pH of only 0.1 to 0.2. In in vivo studies with 
multicellular spheroids and BxPC-3 tumor models these nanoassemblies showed 
improved activity as compared to their non-switching counterparts. Calderón et al. 
reported a hPG/PEG CS system with DOX coupled to the core via a hydrazide 
linker.[105] pH-dependent liberation of DOX was demonstrated in vitro and when 
applied to a ovarian carcinoma A2780 xenograft model, the anti-cancer activity 
exceeded the one of free DOX. 
 
 Figure 13. Chemical structure of a pH-cleavable CMS nanocarrier (left). Cleavage kinetics of the pH sensitive 
imine bond at different pH values. See text for more details. Reproduced with permission from Elsevier.[106] 




























A pH-responsive CMS nanocarrier was presented by Fleige et al. in 2014.[106] Into 
the parent CMS architecture, an imine linker was introduced between core and inner 
shell. While particle showed only slow degradation under pH 7.4 and 6, accelerated 
decomposition took place at pH values of 5 and 4 (see Figure 13). And when applied 
to A549 lung cancer cells in vitro, DOX loaded to pH-cleavable nanocarriers exhibited 
a higher toxicity compared to their DOX-loaded non-cleavable counterparts.  
The presence of enzymes can be exploited by providing a specific substrate, which 
involves in many cases its cleavage, namely, of an ester or an amide bond. This 
means usually the (partial) degradation of the carrier scaffold or the cleavage of the 
linker structure that connects the pharmacophore to the carrier. Mao and Gan 
prepared polymeric micelles with a PG-b-PCL-copolymer to which pyrene could be 
loaded.[107] These micelles were then used to examine the degradation of this 
copolymer by a lipase. Even though the degradable polyester core was shielded by 
non-degradable PEG chains, the authors observed a decrease in fluorescence 
intensity of the cargo pyrene. These results indicated that by the dynamic exchange 
the polymeric amphiphiles become accessible and degradable and thus a triggered 
release can be facilitated. In a prodrug approach, Calderón et al. coupled DOX and 
methotrexate, respectively, to a hPG backbone via two different peptide substrates for 
the enzyme cathepsin B.[108] The conjugates were proven to be non-toxic and the 
incubation with cathepsin B led to the release of the drug. Khandare et al. prepared 
paclitaxel prodrugs by coupling it to a PAMAM dendrimer through two ester bonds and 
a flexible PEG-linker.[109] Incubation with an enzyme led to liberation of the original 
drug and when the constructs were applied on ovarian carcinoma cells, they showed 
an increased toxicity compared to the free drug, indicating uptake and cleavage of the 
conjugate. 
1.5 Dermal Drug-Delivery 
Skin is the most accessible organ of the body and thus has great potential as a drug 
delivery route.[110] But it’s also the reason why nature has fortified its natural barriers 
to prevent the entrance of xenobiotics. Aiming at dermal drug delivery, the goal is to 
overcome the natural barriers, that are closely related to the skin’s structure, with least 
possible irritation. The skin comprises of three major layered parts: hypodermis, 
dermis, and epidermis.[111] The uppermost layer, the epidermis, can again be 





granulosum, which is only covered by the stratum corneum. While the dermis is 
vascularized, the epidermis does not contain any blood vessels. Its major part consists 
of keratinocytes together with a low percentage of melanocytes, which are responsible 
for the production of UV-protecting melanin and Langerhans cells, the outposts of the 
immune system in skin. As dermal regeneration is a dynamic process involving the 
migration of skin cells, the keratinization increases with the different layers, to finally 
yield dead terminally differentiated corneocytes forming the stratum corneum (SC).  
 
Figure 14: Schematic depiction of the skin's layered structure and the two major penetration pathways for 
nanomedicines. Reproduced with permission from Elsevier.[110] 
This outermost layer is the first physical barrier of the skin which needs to be overcome 
for successful drug delivery. It comprises flattened, hexagonally shaped corneocytes 
containing fibrous keratin which are surrounded by extracellular lipids. It is commonly 
described as brick and mortar model.[112] In addition to this basic description,  
corneodesmosomes and anchoring structures are important structural features that 
contribute to mechanical stability. In principle, there are three different pathways 
through skin of which two lead through the SC in a more or less direct manner.[113] 
The intracellular pathway describes the way through the SC passing through the dead 
corneocytes, while the more important intercellular one leads around them. In addition, 
there is a third, follicular pathway. Hair follicles are shunts through the skin barrier and 
thus pose an attractive drug delivery route. The follicles roots deeply into the dermis, 
but in addition to a hair growing out of the follicle, the sebaceous gland excretes 





While there is a “500 Da rule” for dissolved small molecule to cross the skin 
barrier,[114,115] the situation is much more complicated for nanoparticles. Whether 
and how deep a nanotransporter penetrates skin and by which mechanism is a matter 
of a multitude of factors. Such factors include deformability, charge and shape, but the 
most important factor is size.[113] A multitude of nanoparticles of different sizes and 
materials was tested for skin penetration. While particles like liposomes, which are 
comprised of small molecules, usually disintegrated into their building blocks while 
entering the SC, polymeric and inorganic particles mostly only penetrated the top part 
of the SC. The hair follicle, however, was penetrated by nanoparticles of various sizes. 
Vogt et al. reported the increased uptake into hair follicles and Langerhans cells of 
40 nm-sized particles compared to particles with a diameter of 750 and 1500 nm.[116] 
In contrast to that, a different size dependence was observed by Patzelt et al. They 
applied PLGA and SiO2 particles of a size from 122 to 1000 nm to porcine skin using 
a massager for three minutes.[117] In the subsequent analysis, the particle showed 
different penetration depths with a maximum at around 640 nm particle size. This 
optimum was attributed to the combination of vibrational massage and the hair’s 
sawtooth-like surface structure, and postulated a “ratchet”-like mechanism, which was 
also described in theoretic models.[118] In diseased skin, penetration of nanoparticles 
can be different from the normal state. Psoriasis and atopic dermatitis alter the 
differentiation of the corneocytes, lipid composition, and organization. In general, 
these changes lead to an impaired barrier function and thus to increased penetration 
of nanoparticles.[119,120] 
There are several types of polymeric nanocarriers that have been used for the 
transport of biologically active agents. Amphiphilic polymeric architectures can 
enhance the penetration of a loaded guest molecule. Xing et al. reported nanoparticles 
based on an amphiphilic graft copolymer which were loaded with tetrahydropalmatine 
(THP). In an evaluation in vitro on a Franz cell setup, the particles did not only transport 
THP through the skin but also penetrated the skin themselves.[121] In a similar setup, 
Conte el al. used a PEG-co-PCL block copolymer for the encapsulation and 
penetration enhancement of a Zn-phthalocyanine (ZnPc). While without β-CD, the 
ZnPc penetrated skin only poorly, the addition of a β-cyclodextrin could enhance skin 
penetration depth significantly. A similar type of amphiphilic polymeric structure, the 





Küchler et al. applied dye-loaded CMS nanotransporters on pig skin ex vivo and found 
their penetration-enhancing effect superior over the one of solid lipid nanoparticles.[85] 
In a subsequent study,[122] the same Nile red-loaded nanocarrier and an unloaded 
dye-labeled analog were compared regarding their penetration on normal and stripped 
skin human skin ex vivo (see Figure 15). While Nile red penetrated rapidly even after 
6 h incubation time in deep skin layers, the nanocarrier could only be found in the SC 
after this period. However, penetration of the nanocarrier could be enhanced by tape-
stripping or an extended incubation time. These results showed that CMS nanocarriers 
are promising candidates for the dermal drug delivery of small hydrophobic drugs. 
 
Figure 15. Penetration of ICC-labeled CMS nanocarriers and NR (0.004%, loaded into CMS nanotransporters) into 
normal (white bars) and tape-stripped (grey bars) human skin. Incubation times were 6 h (open columns) and 24 h 
(striped columns). A. Overlay images of fluorescence and bright field microscopy. B. Quantification of fluorescence 
intensity into arbitrary brightness units (ABU) in the different skin layers ± standard error of the mean, n = 3, scale 
bar 100 µm, p* ≤ 0.05, reprinted with permission from Elsevier.[122] 
As amphiphilic nanocarriers are more suitable for hydrophobic small drugs, bigger and 
more hydrophilic structures are the obvious choice for biomolecules like proteins or 
DNA. In a study by Witting et al. hPG was crosslinked with PNIPAM to yield 
thermoresponsive nanocarriers with a trigger point at 35 °C.[123] Exceeding this 
trigger point, the nanogels released 93% of the loaded protein. Subsequent skin 
penetration experiments on barrier-deficient skin resulted in the successful delivery of 





2 Scientific Goals 
CMS nanocarriers are a versatile platform for the solubilization of a variety of 
compounds and can be used for the delivery of a multitude of pharmacophores to 
certain sites in the human body. Drug targeting to tumors, has been facilitated as well 
as penetration enhancement into skin. To improve the current approaches and tackle 
unsolved problems, novel CMS architectures have to be explored. This work can be 
subdivided into two parts. The first one will deal with biocompatible and biodegradable 
CMS-nanocarriers for the encapsulation of hydrophobic drugs and the enhanced 
penetration into skin. In the second part, a CMS nanoarchitecture will be designed for 
the binding and pH-dependent release of a small cationic analgesic.  
The skin is a strong barrier that has to be overcome in order to improve dermal delivery 
for an efficient treatment. CMS nanocarriers have become promising candidates to 
enhance the penetration of hydrophobic drugs. To improve this architecture, crucial 
issues have to be addressed, such as ease of synthesis, degradability, nontoxicity of 
building blocks, and controlled release. In addition, it is important to investigate the 
drug-carrier interaction. To this point, it is known that hydrophobic interactions play a 
key role in the encapsulation process. However, only little attention was paid to 
aspects like chain length, branching, and the type of bond used to attach the 
amphiphilic double shell. Additional factors are defined by the drug itself. Hydrophobic 
drugs can vary strongly with respect to polarity, size and rigidity, which can influence 
the interaction with a DDS. To investigate this, two structurally different hydrophobic 
Figure 16. Schematic illustration of the synthetic strategies. grey circle = hPG core, green/blue wedge = amphihilic 





anti-inflammatory drugs, which are important for the treatment of auto-inflammatory 
skin diseases, will be investigated regarding their loading into architectural various 
CMS nanotransporters. 
Degradability is a crucial to avoid accumulation in the tissue during in vivo applications 
but can also be controlled release mechanism. Hence, the goal is to redesign the 
synthesis to yield biodegradable, ester-based carriers. This strategy has two 
advantages, it reduces the number of synthetic steps and avoids the formerly used, 
potentially toxic building block hPG-NH2. The final products will then be tested 
regarding their degradability both in vitro and in vivo and with respect to the controlled 
release of a hydrophobic drug. Toxicity of not only of the CMS architectures but also 
of their building blocks will also be determined. Finally, the penetration of the carriers 
and the guest molecules will be quantified on different skin models, including excised 
human skin, an inflammatory skin model, and murine oral mucosa.  
U 50,488H is a strong analgesic with potential application in post-operative pain 
treatment, which is cationic under physiological conditions. However, there are severe 
side effects which only occur when the drug crosses the blood brain barrier. After an 
operation, the tissue is inflamed and thus exhibits a lower pH. The goal is to use these 
conditions to design a functionalized nanocarrier for the transport and pH-dependent 
Figure 17. Different release mechanisms for the two CMS nanocarriers. Enzymatic degradation (left) and 




























release of U 50,488H. To achieve this, the architecture of the CMS nanocarrier will be 
extended by an anchor moiety, which can bind U 50,488H via ionic interaction, π-π 
stacking and hydrogen bonding. After synthesis and characterization, the drug-loading 
properties of the nanocarriers will be determined. The release-kinetics of U 50,488H 
from the carrier will be measured under various conditions to quantify the retention 
effect. Finally, a selected carrier will be tested in a rat model for in vivo performance. 
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Abstract: We here present the synthesis and characterization of a set of biodegradable core–multishell
(CMS) nanocarriers. The CMS nanocarrier structure consists of hyperbranched polyglycerol (hPG)
as core material, a hydrophobic (12, 15, 18, 19, and 36 C-atoms) inner and a polyethylene glycol
monomethyl ether (mPEG) outer shell that were conjugated by ester bonds only to reduce the toxicity
of metabolites. The loading capacities (LC) of the drugs, dexamethasone and tacrolimus, and the
aggregate formation, phase transitions, and degradation kinetics were determined. The intermediate
inner shell length (C15) system had the best overall performance with good LCs for both drugs as
well as a promising degradation and release kinetics, which are of interest for dermal delivery.
Keywords: biodegradable CMS nanocarrier; drug delivery; dendritic polymers; dexamethasone;
tacrolimus
1. Introduction
Cutaneous drug delivery is the method of choice when skin is the target and systemic side effects
are to be avoided. This is especially the case in inflammatory skin diseases such as psoriasis and atopic
dermatitis. The drugs, e.g., the commonly used dexamethasone and tacrolimus, must penetrate the skin
first, which is the body’s natural barrier against xenobiotics. Especially the outermost layer, the stratum
corneum, has to be overcome to reach the target, namely, the skin’s viable layers. Amphiphiles, among
other penetration enhancers, are extensively used to facilitate a deeper penetration [1]. The application
of nanoparticles, which have attracted much attention in recent years [2], has been widely explored.
A nanoparticle can either consist of only the drug or be a carrier particle that contains the respective
agents. The nanoparticles are classified according to their size, shape, and charge and are categorized
into hard and soft, biological, organic, and inorganic particles. The skin offers different pathways for
various types of nanoparticles that address one or more of the transdermal pathways, the intracellular,
intercellular, or the follicular pathway, and also target the sebaceous gland [3]. Particulate formulation
has been shown to enhance both the uptake of drugs into skin in general [4,5] but also specifically
into hair follicles in a size-dependent manner [6,7]. Some of the polymeric particles that are reported
in the literature contain esters or are ester-based (e.g., PCL [8], PLA [6], PLGA [7]) and thus are
principally biodegradable.
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Amore sophisticated structure is the so-called core–multishell (CMS) nanocarrier that extends
the idea of the unimolecular micelle to the parent structure of a unimolecular liposome [9–11].
While a unimolecular micelle consists of simple, usually hydrophilic polymeric chains anchored
to a dendritic core [12], the CMS nanocarrier is a unimolecular structure that has a branched core-unit
with amphiphilic polymeric chains attached to it, which at least consist of one hydrophilic and
one hydrophobic block (see Figure 1). Frequently used core structures are the polyester Boltorn®
H40 [13,14], poly (ethyleneimine) (PEI) and the highly hydrophilic hyperbranched polyglycerolamine
(hPG-NH2) [15,16]. Initially designed as a unimolecular liposome, the CMS nanotransporter has been
reported by our group for the transport of both hydrophilic and lipophilic guest molecules [11,15].
The CMS nanocarrier can solubilize hydrophobic guest molecules in a hydrophilic environment
and vice versa [16]. In contrast to other drug delivery systems (DDS), the mode of solubilization is
physical entrapment upon which larger aggregates are formed. The CMS nanocarrier and its differently
functionalized derivatives have been successfully used for the transport of the fluorescence dye ITCC
in a tumor xenograft model as well as the penetration enhancement of the model drug Nile Red
into skin [16,17]. Their aggregation phenomena and host–guest interactions have been studied both
experimentally and theoretically [18,19].
The long-term toxicity of the polymeric DDS is an important issue when it comes to in vivo
applications. Not only the polymer assemblies but also their degradation products have to be
taken into consideration. The usage of polyamines can be especially problematic: Their polycationic
character enables interaction with the positively charged cellular membranes and can be a source
of cytotoxicity [20]. In the case of hPG–NH2, another drawback is the synthetic effort. Three
synthetic steps are necessary to convert the hyperbranched glycerol (hPG) to its amino-functionalized
derivative [21].
Complementary to a previous biological study [22], here we present esterification as a promising
alternative to amide formation for the synthesis of the CMS nanocarriers. Furthermore, the influence
of different chain length, branching of inner shell, the type of chemical bond on melting point, and
drug loading behavior of dexamethasone and tacrolimus are investigated.
 
Figure 1. Structure of an ester-based CMS nanocarrier.
2. Materials and Methods
All chemicals were used as bought without any further purification. Polyethylene
glycol monomethyl ether (mPEG) 350 was bought from Sigma-Aldrich, Munich, Germany.
1,18-Octadecandioic acid was a kind gift from Cognis, Monheim am Rhein, Germany.
1,19-nonadecanedioic acid was received as the dimethyl ester from the Mecking group, Konstanz,
Germany [23]. The branched C18b-diacid was a gift from Cognis (see Scheme S1 for composition
30
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and purification). 1,12-Dodecandioic acid was bought from Sigma Aldrich, St. Louis, MI, USA and
1,15-pentadecandioic acid was bought from ToniChemPharma (Huizhou, China). hPG and CMS-A18
were produced by previously published methods [21,24].
Methanol was bought from Sigma-Aldrich; dry pyridine was bought from Acros, Geel, Belgium
and stored over calcium hydride (Acros). Dry DCM was taken from solvent purification system
(SPS-800) by MBRAUN (Stratham, NH, USA) and stored over a molecular sieve (4 Å, Roth).
2.1. Nuclear Magnetic Resonance (NMR)
NMR spectra were recorded either on a Jeol Eclipse 500 MHz (Tokyo, Japan) or a Bruker AVANCE
III 700 MHz spectrometer (Billerica, MA, USA). Proton and carbon NMR were recorded in ppm and
were referenced to the indicated solvents [25]. NMR data were reported including: chemical shift,
multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), integration, and coupling constants (s)
in Hertz (Hz). Multiplets (m) were reported over the range (ppm) in which they appear in the spectrum.
All spectra were recorded at 300 K.
2.2. Infrared (IR) Spectroscopy
IR spectra were recorded on a Jasco FT/IR 4100LE spectrometer (Groß-Umstadt, Germany)
equipped with a MIRacleTM single reflection ATR device from PIKE Technologies (Fitchburg, WI,
USA). Samples were directly placed on the ATR crystal. Data recording and analysis was done with
Spectra Manager® II software from Jasco.
2.3. Dynamic Light Scattering (DLS)
For the determination of hydrodynamic sizes, dynamic light scattering (DLS) measurements were
performed on a Malvern Zetasizer Nano (Herrenberg, Germany) equipped with a laser at 532 nm using
backscattering mode (detector angle 173◦). The samples were filtered through 0.45 µm regenerated
cellulose syringe filters prior to DLS measurement and 100 µL of the resulting solution added to
a disposable micro-cuvette. Autocorrelation functions were analyzed using Zetasizer DTS software
(Malvern, Herrenberg, Germany) to determine the size distribution by intensity or number. The
fraction (%) indicates the proportion of measured size relative to the total signal scattered by the CMS
nanocarriers. Measurements were performed at 25 ◦C if not stated otherwise.
2.4. Gel Permeation Chromatography
A Shimadzu (Kyoto, Japan) liquid chromatography (LC) system was employed for the gel
permeation chromatography (GPC) measurements. Three PolarSil columns (PSS Polymer Standards
Service GmbH, Germany; PolarSil 8 × 300 mm, 100 Å, 1000 Å, 3000 Å with 5 µm particle size) and
a refractive index detector (RI) were used to separate and analyze polymer samples. As the mobile
phase DMF (0.3 wt % LiBr and 0.6 wt % acetic acid) was used at a flow rate of 1 mL·min−1. Columns
and RI detector were heated to 40 ◦C. The system was calibrated against polystyrene calibration
standards (PSS, Germany). Samples were measured at a concentration of 10 mg·mL−1. LC solution
software from Shimadzu was used for data analysis.
2.5. Film Encapsulation Method
The film uptake method was chosen for the encapsulation procedure. To form a film, 50 wt % of
the guest compound (dexamethasone or tacrolimus) was dissolved in a vial and the solvent removed
on a rotavap. A stock solution of the respective CMS nanocarrier (5 mg·mL−1) was filled onto the
film and the suspension stirred for 22 h at room temperature. Excess guest was removed via filtration
through a 450 nm RC syringe filter. The same procedure was carried out at 60 ◦C for the CMS-E19
nanocarrier, which was poorly soluble at low temperatures.
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2.6. HPLC Analysis
The guest concentration was determined via high performance liquid chromatography (HPLC,
Phenomenex Gemini, Torrance, CA, USA, C18, 5 µm 110 Å, 250 mm × 6.4 mm, flow 1 mL·min−1,
210 nm, 40% acetonitrile/H2O for dexamethasone, acetonitrile for tacrolimus) using a UV detector
set to λ = 210 nm. For the preparation of the sample, the samples were diluted with acetonitrile
(dexamethasone) or lyophilized and redissolved in acetonitrile (tacrolimus).
2.7. Determination of Enzymatic Activity
The enzymatic activity of Rhizomucor miehei lipase was determined photometrically similar to
a previously published method [26]. First, 5–10 µL of the diluted enzyme solution was added to
a solution of 1 mM 4-nitrophenyl acetate in PBS (1% acetonitrile, total volume 1 mL). After 1 h
stirring at 200 RPM and 32 ◦C, the concentration of the reaction product 4-nitrophenol was determined
photometrically using a spectrophotometer and the extinction coefficient of 4-nitrophenol (ε = 11.9 ×
103 M−1·cm−1, λ = 400 nm). A sample without enzyme was used to deduct the fraction of thermal
hydrolysis. One unit of enzymatic activity equals the release of 1 µmol 4-nitrophenol per minute.
2.8. Enzymatic Degradation
To determine the rate of enzymatic degradation, a solution of CMS nanocarrier (5 mg·mL−1)
in PBS was prepared and lipase from Rhizomucor miehei (8 mU·mg−1 polymer) was added. The
solutions were stirred with a small stir bar at 200 RPM at 32 ◦C. Samples were taken at different time
points, lyophilized, redissolved in DMSO-d6 and analyzed via NMR. Due to the high consumption of
material, the experiment was only performed once.
2.9. Release by Enzymatic Degradation
To measure the release of the drug from an enzymatically degraded carrier, a solution of
dexamethasone-loaded CMS nanocarrier in PBS was prepared (10 mg mL−1 polymer), Rhizomucor
miehei lipase (8 mU·mg−1 polymer) added (or not added in the case if the untreated control (UC)) and
the solution stirred at 200 RPM. At different time points, the solution was centrifuged for 10 min at
4000 RPM (Heraeus Biofuge Primo), the supernatant sampled and stirring was continued. Samples
were either diluted with acetonitrile before measurement with HPLC to match the eluent.
2.10. Synthesis
1,19-Nonadecandioic Acid
Following a previously published procedure [23], dimethyl-1,19-nonadecanedioate (854.9 mg,
2.4 mmol) was suspended in 6.4 mL methanol and the suspension heated to 70 ◦C (oil bath). After
dissolution, a solution of 1.8 g (31.4 mmol) KOH in 6.4 mL Methanol was added dropwise and the
solution was stirred overnight at 70 ◦C. The methanol was distilled off and the residue dissolved in
water. Then it was acidified via the addition of 3 M HCl to a pH of 1. The precipitate was filtered off
with a glass frit, washed with water, and dried in the air stream of the pump. The product could be
isolated as 764 mg (2.3 mmol) of a colorless solid (yield 97%).
1HNMR: (DMSO-d6, 500 MHz, TMS): δ 2.17 (t, 2H, J = 7.4 Hz, 4H, HOOC–CH2–); 1.51–1.43 (m, 4H,
HOOC–CH2–CH2–); 1.28–1.20 (br s, 26H, –CH2– backbone). 13C NMR: (DMSO-d6, 125 MHz, TMS): δ
174.42 (HOOC–CH2–), 33.66 (HOOC–CH2–), 29.03–28.54 (HOOC–CH2–CH2–), 24.49 (–CH2– backbone).
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2.11. Double-Shell Building Blocks
2.11.1. C12-mPEG350
In a three-neck flask equipped with a gas inlet, thermometer with quick fit, and septum, a mixture
of mPEG350 (0.3 mol, 1 equiv.) with dodecanedioic acid (C12, 0.9 mol, 3 equiv.) was stirred under high
vacuum and heated to 120 ◦C. The mixture was kept at this temperature for at least 1.5 h until a clear
melt was obtained. The temperature was then raised to 180 ◦C and stirred for an additional 4.5 h.
The reaction mixture was kept under vacuum and allowed to cool to 120 ◦C. While still a melt, the hot
reaction mixture was transferred to a beaker and cooled to room temperature. The still warm waxy
solid was chopped, 2 L of methylene chloride added, and the resulting mixture vigorously stirred until
a near homogeneous suspension was formed. The suspension was filtered and the filtrate concentrated
to a final volume of 600 mL by rotary evaporation. The solution was kept a 5 ◦C for 18 h. Precipitated
excess C15 was removed by filtration. The remaining filtrate was concentrated by rotary evaporation
and subsequently dried under high vacuum to yield a colorless wax (69%) of C12-mPEG350.
1H NMR (500 MHz, methanol-d4, TMS): δ (ppm) = 4.22–4.18 (m, 2H, –CH2–OCO–), 3.75–3.50 (m, 30H,
mPEG backbone), 3.36 (s, 3H, –O–CH3), 2.33 (t, 2H, J = 7.4 Hz, ROOC–CH2–CH2–), 2.28 (t, 2H, J = 7.4
Hz, HOOC–CH2–CH2–), 1.65–1.55 (m, 4H, –CO–CH2–CH2–), 1.37–1.20 (m, 12H, –CH2–(CH2)6–CH2–).
13C NMR (125 MHz, methanol-d4, TMS): δ (ppm) = 177.4, 175.2, 72.9, 71.7–71.3, 70.3, 70.1, 64.5, 64.3,
59.1, 59.1, 34.9, 34.9, 30.7, −30.1, 26.0, 26.0. IR (cm−1): 2923, 2856, 1732, 1456, 1349, 1247, 1099, 1040,
946, 849, 724. GPC: Mn = 680 g·mol−1, Mw = 750 g·mol−1, PDI = 1.10.
2.11.2. C15-mPEG350
C15-mPEG350 was synthesized in analogy to C12-mPEG350. The reaction of mPEG350 (0.3 mol,
1 equiv.) and 1,15-pentadecanedioic acid (0.9 mol, 3 equiv.) resulted in C15-mPEG350 as a pale-yellow
wax (68% yield).
1H NMR (500 MHz, methanol-d4, TMS): δ (ppm) = 4.22–4.18 (m, 2H, –CH2–OCO–), 3.75–3.50 (m, 30H,
mPEG backbone), 3.36 (s, 3H, –O–CH3), 2.33 (t, 2H, J = 7.4 Hz, ROOC–CH2–CH2–), 2.28 (t, 2H, J = 7.4
Hz, HOOC–CH2–CH2–), 1.65–1.55 (m, 4H, –CO–CH2–CH2–), 1.37–1.20 (m, 18H, –CH2–(CH2)9–CH2–).
13C NMR (125 MHz, methanol-d4, TMS): δ (ppm) = 177.5, 175.3, 72.9, 71.6–71.5, 71.3, 70.1, 64.5, 59.1,
34.9, 34.9, 30.7, −30.1, 26.0, 26.0. IR (cm−1): 2922, 2854, 1733, 1456, 1349, 1248, 1099, 1040, 946, 850, 723.
GPC: Mn = 680 g·mol−1, Mw = 735 g·mol−1, PDI = 1.08.
2.11.3. C18-mPEG350
Similar to an already published method [15], 14.9 g (42.7 mmol) methoxy-poly(ethylene glycol)
(mPEG) 350 (dried overnight at 70 ◦C under low pressure (5 × 10−2 mbar) and 47.7 g (15.2 mmol)
1,18-octadecanedioic acid were added without solvent into a Schlenk flask. The reaction mixture
was heated up to 185 ◦C and the reaction mixture was stirred vigorously for 3 h under vacuum
(5 × 10−2 mbar). After 3 h, a sample was taken and submitted for NMR, the mixture was allowed
to cool down to 140 ◦C, and a reflux condenser was installed. Then, 300 mL toluene was added into
the flask. While still stirring, the reaction mixture was slowly allowed to cool down to 0 ◦C. The
resulting suspension was filtrated and the white residue was washed with 300 mL of cold (0 ◦C)
toluene. The filtrate and washings were combined and concentrated by rotary evaporation in vacuo
and the remaining solvent removed in vacuo at 50 ◦C. Of the pre-purified product (19.8 g, 72% yield),
5 g were purified via HPLC (Phenomenex Gemini, C18, 5 µm, 110A, 250 mm × 21.2 mm, flow 20 mL
min−1, 210 nm, 95% MeOH/H2O) to yield 3.9 g of a white wax (yield 56%).
1H NMR (700 MHz, methanol-d4, TMS): δ (ppm) = 4.21 (m, 2H, –CH2–OOC–), 3.71–3.52 (m, 28.4H,
mPEG backbone), 3.36 (s, 3H, –O–CH3), 2.34 (t, 2H, J = 7.4 Hz, 2H, R–OOC–CH2–CH2–), 2.28 (t,
2H, J = 7.4 Hz, 2H, –HOOC–CH2–CH2–), 1.65–1.54 (m, 4H, –OOC–CH2–CH2–), 1.38–1.25 (br s, 24H,
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–CH2–(CH2)12–CH2–). 13C NMR (176 MHz, methanol-d4, TMS): δ (ppm) = 177.57, 175.35, 72.96,
71.75–71.25, 70.15, 64.55, 35.00–34.90, 30.80–30.15, 26.12–26.00. IR (cm−1): 2916, 2848, 1730, 1702, 1462,
1342, 1243, 1106, 954, 848, 729. GPC: Mn = 830 g·mol−1, Mw = 920 g·mol−1, PDI = 1.11.
2.11.4. C19-mPEG350
C19-mPEG350 was synthesized analog to C18-mPEG350. In total, 1.8 g (5.0 mmol) mPEG350
and 4.9 g (15.0 mmol) 1,19-nonadecanedioic acid led to 2.4 g (3.7 mmol) of the colorless solid product
(74% yield).
1H NMR (700 MHz, methanol-d4, TMS): δ 4.21 (m, 2H, –CH2–OOC–), 3.71–3.52 (m, 26.8H, mPEG
backbone), 3.36 (s, 3H, –O–CH3), 2.33 (t, 2H, J = 7.4 Hz, 2H, R–OOC–CH2–CH2–), 2.28 (t, 2H,
J = 7.4 Hz, 2H, –HOOC–CH2–CH2–), 1.64–1.57 (m, 4H, –OOC–CH2–CH2–), 1–1.27 (br m, 26H,
–CH2–(CH2)12–CH2–). 13C NMR: (176 MHz, methanol-d4, TMS): δ 177.58, 175.34, 72.97, 71.65–71.50,
71.37, 70.16, 64.56, 59.10, 34.99, 34.94, 30.85–30.15, 26.10, 26.03. IR (cm−1): 2917, 2848, 1729, 1694, 1463,
1345, 1234, 1105, 961, 847, 730. GPC: Mn = 840 g·mol−1, Mw = 920 g·mol−1, PDI = 1.10.
2.11.5. C18b-mPEG750
8.5 g C18b-diacid (15.0 mmol) and 2.8 g mPEG750 (3.7 mmol) were added into a Schlenk flask
and stirred at 60 ◦C for 30 min. Afterwards, the reaction mixture was heated to 180 ◦C and stirred
under high vacuum (<0.5 × 10−2 mbar) for 3 h. After cooling down, the mixture was purified via
column chromatography using the eluents chloroform/acetic acid (80:1), chloroform/methanol 20:1,
and methanol, which yielded the product as 3.8 g of a yellow oil (yield 78%).
1H NMR: (700 MHz, methanol-d4, TMS): δ 6.85 (m, 0.4H, arom. –H), 4.21 (m, 2H, –CH2–OOC–),
3.75–3.50 (m, 63.2H, mPEG backbone), 3.36 (s, 3H, –O–CH3), 2.54 (m, 1.6H, benzyl–H), 2.33 (t, 2H,
J = 7.1 Hz, 2H, R–OOC–CH2–CH2–), 2.28 (t, 2H, J = 7.1 Hz, 2H, HOOC–CH2–CH2–), 1.64–1.50 (m, 8.2H,
–OOC–CH2–CH2– + –CH2–CH2–Ph), 1.5–1.1 (br s, 44.5H, aliph. backbone), 0.91 (m, 3H, –CH2–CH3).
GPC: Mn = 1380 g mol−1, Mw = 1610 g mol−1, PDI = 1.17. 13C NMR: (176 MHz, methanol-d4, TMS):
δ 177.50, 175.28, 72.98, 71.87–71.05, 70.17, 64.57, 59.11, 34.98, 33.08, 31.05–29.95, 26.12, 23.76, 14.52. IR
(cm−1): 2921, 2855, 1732, 1456, 1349, 1249, 1101, 947, 850, 722.
2.12. Nanocarriers
2.12.1. CMS-E12
To link the shell components with the hPG core (Mn = 9.9 kDa; Mw = 15.8 kDa), 141 g
C12-mPEG350 (0.3 mol, 1 equiv.) were dissolved in 625 mL anhydrous methylene chloride in
a three-necked flask equipped with a gas inlet and two septa. The solution was cooled down to
0 ◦C and 25.9 mL thionyl chloride (42.5 g, 0.4 mol, 1.5 equiv.) was added. One septum was then
replaced with a reflux condenser connected to two washing flasks, the second of which was filled with
sodium hydroxide solution. The reaction was refluxed for 4.5 h. Methylene chloride and the excess of
thionyl chloride were removed by cryo-distillation, and the residue dried for a further 3 h under high
vacuum. In the meantime, 26 g hPG (2.6 mmol) were dissolved in 530 mL dry pyridine. The resulting
acid chloride was dissolved in 200 mL dry methylene chloride and added dropwise to the hPG solution.
The reaction was stirred overnight and then quenched by the addition of methanol (1.48 mol). Solvents
were then removed with a rotary evaporator. The crude product was purified with a Millipore bench
scale tangential flow field filtration system, equipped with a 30 kDa·MW cut-off membrane and at least
250 mL of distilled water per gram CMS nanocarrier. The product was freeze-dried, which yielded
117 g of a clear viscous yellow oil of CMS-E12 (62%).
1H NMR (500 MHz, DMSO-d6, TMS): δ (ppm) = 4.09 (s, 2H, –CH2–OCO–), 3.69–3.25 (m, 37H, mPEG
repeating unit and hPG backbone), 3.23 (s, 3H, –O–CH3), 2.25 (m, 4H, –CH2–COO–), 1.49 (m, 4H,
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–CH2–CH2–COO–), 1.22 (m, 12H, –(CH2)6–). 13C NMR (125 MHz, DMSO-d6, TMS): δ (ppm) = 172.7,
71.3, 69.9–69.6, 68.4, 63.0, 58.0, 33.4, 29.3–28.4, 24.5. IR (cm−1): 3462, 2922, 2856, 1732, 1456, 1349, 1248,
1100, 948, 850, 723. GPC: Mn = 32,200 g·mol−1, Mw = 42,200 g·mol−1, PDI = 1.31.
2.12.2. CMS-E15
CMS-E15 was synthesized in analogy to CMS-E12. In total, 151 g (0.3 mol) C15-mPEG350 were
reacted with 25.9 mL thionyl chloride (42.5 g, 0.4 mmol) and 26 g (2.6 mmol) hPG (Mn = 10.4 kDa;
Mw = 16 kDa) to yield 138 g of a yellow to brown oil (79%).
1H NMR (500 MHz, DMSO-d6, TMS): δ (ppm) = 4.09 (s, 2H, –CH2–OCO–), 3.69–3.25 (m, 30H, mPEG
repeating unit and hPG backbone), 3.23 (s, 3H, –O–CH3), 2.25 (m, 4H, –CH2–COO–), 1.49 (m, 4H,
–CH2–CH2–COO–), 1.21 (m, 18H, –(CH2)9–). 13C NMR (125 MHz, DMSO-d6, TMS): δ (ppm) = 172.7,
71.3, 69.9–69.6, 68.3, 63.0, 58.0, 33.4, 29.3–28.4, 24.5. IR (cm−1): 3460, 2922, 2853, 1733, 1456, 1349, 1248,
1100, 949, 851, 722. GPC: Mn = 41,100 g·mol−1, Mw = 59,100 g·mol−1, PDI = 1.44.
2.12.3. CMS-E18
hPG (480 mg, 6.5 mmol OH groups, Mn = 8.1 kDa; Mw = 16.2 kDa) was dried by dissolving in
5 mL of anhydrous pyridine and evaporating the solvent. Then it was dissolved in 38 mL dry pyridine.
C18-mPEG350 (1.7 mmol, 7.5 g, previously dried at 50 ◦C under vacuum <5 × 10−2 mbar overnight) in
a three-neck flask (equipped with a reflux-condenser, an olive and a septum) was dissolved in 38 mL
dry methylene chloride. At 0 ◦C, 1.27 mL thionyl chloride were added and after 10 min the temperature
was increased to the boiling point of methylene chloride. After 2 h, the solvent was evaporated by
cryo-distillation. At 0 ◦C, the intermediate was dissolved in dry pyridine and the solution was added
dropwise to the solution of hPG. After stirring overnight, the solvent was distilled off and the crude
product purified with dialysis (5 kDa, 3 × 3 L) and ultrafiltration (MWCO 30 kDa, methanol) yielding
the product as a viscous, brownish oil (2.7 g, 78%).
1H NMR (700 MHz, methanol-d4, TMS): δ (ppm) = 4.21 (s, 2H, –CH2–OCO–), 3.72–3.52 (m, 31.7H,
mPEG repeating unit and hPG backbone), 3.36 (s, 3H, –O–CH3), 2.34 (m, 4H, –OOC–CH2–), 1.62 (m,
4H, –OOC–CH2–CH2–), 1.31 (m, 24H, –(CH2)12–). 13C NMR (176 MHz, methanol-d4, TMS): δ (ppm) =
175.0, 73.0, 71.6–71.4, 70.2, 64.6, 59.2, 35.0, 31.0–30.4, 26.2. IR (cm−1): 3445, 2922, 2852, 1733, 1456, 1349,
1248, 1103, 949, 851, 722. GPC: Mn = 34,900 g·mol−1, Mw = 49,200 g·mol−1, PDI = 1.41.
2.12.4. CMS-E19
88.3 mg hPG (1.2 mmol OH groups, Mn = 6.9 kDa; Mw = 12.4 kDa) was dried by dissolving in
1 mL of anhydrous pyridine and evaporating the solvent. Then the residue was dissolved in 7 mL dry
pyridine. C19-mPEG350 (2.4 mmol, 1.6 g, previously dried at 50 ◦C under vacuum <5 × 10−2 mbar
overnight) in a three-neck flask (equipped with a reflux-condenser, an olive, and a septum) was
dissolved in 8 mL dry methylene chloride. At 0 ◦C, 0.3 mL thionyl chloride were added and after
10 min the temperature increased to the boiling point of methylene chloride. After 2 h, the solvent was
evaporated by cryo-distillation. At 0 ◦C, the intermediate was dissolved in dry methylene chloride
and the solution was added dropwise to the solution of hPG. After stirring overnight, the solvent was
distilled off and the crude product purified with dialysis (2 kDa, 3 × 3 L) and ultrafiltration (MWCO
30 kDa, methanol) yielding the product as a colorless solid (284 mg, 64%).
1H NMR (700 MHz, methanol-d4, TMS): δ (ppm) = 4.20 (s, 2H, –CH2–OCO–), 3.72–3.51 (m, 31.3H,
mPEG repeating unit and hPG backbone), 3.35 (s, 3H, –O–CH3), 2.33 (m, 4H, –OOC–CH2–), 1.62 (m,
4H, –OOC–CH2–CH2–), 1.32 (m, 24H, –(CH2)13–). 13C NMR (176 MHz, methanol-d4, TMS): δ (ppm) =
174.9, 73.1z, 71.8–71.4, 70.3, 64.6, 59.3, 35.1, 31.7–30.4, 26.2. IR (cm−1): 3399, 2917, 2850, 1712, 1486, 1306,
1226, 1111, 953, 851, 746. GPC: Mn = 32,300 g·mol−1, Mw = 42,600 g·mol−1, PDI = 1.32.
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2.12.5. CMS-E18b
CMS-E18b was synthesized analog to CMS-E19. In total, 2.2 mg (1.7 mmol) C18b-mPEG750
were reacted with 186 µL thionyl chloride (305 mg, 2.6 mmol) and 105.6 g (1.4 mmol OH groups,
Mn = 6.9 kDa; Mw = 12.4 kDa) hPG to yield after purification with UF (methanol, 30 kDa MWCO)
577 mg of a brown oil (42% yield).
1H NMR (500 MHz, methanol-d4, TMS): δ (ppm) = 7.08–6.69 (m, 0.4H, arom.-H); 4.21 (s, 2H,
–CH2–OCO–), 3.72–3.50 (m, 70.4H, mPEG repeating unit and hPG backbone), 3.36 (s, 3H, –O–CH3), 2.55
(m, 1.6H, benzyl–H); 2.33 (m, 4H, –OOC–CH2–), 1.61 (m, 4H, –OOC–CH2–CH2–, –CH2–CH2–Ph), 1.31
(br s, 44.5H, aliph. backbone); 0.91 (m, 3H, –CH2–CH3). 13C NMR (125 MHz, methanol-d4, TMS): δ
(ppm) = 174.4, 73.0, 71.7–71.3, 70.2, 64.6, 59.2, 35.1, 31.2–30.2, 26.2, 23.9, 15.0. IR (cm−1): 3454, 2922, 2855,
1732, 1456, 1349, 1248, 1098, 949, 849, 756. GPC: Mn = 33,300 g·mol−1, Mw = 56,100 g·mol−1, PDI = 1.68.
2.12.6. CMS-A18
Amide-based CMS nanocarriers CMS-A18 were synthesized according to procedures published
elsewhere [16].
3. Results
3.1. Synthesis of the Ester-Based Core–Multishell Nanocarriers
3.1.1. Synthesis of the Shell Molecule
The double shells of the various CMS architectures were synthesized according to a previously
published procedure [15]. The esterification reaction was conducted without a catalyst at 180 ◦C and
under low pressure (<10−1 mbar, see Scheme 1). To avoid diester formation, stoichiometries of 3–4:1
(diacid to mPEG) were chosen. Purification was either carried out by precipitation (C12 and C15)
or chromatography. Normal column chromatography was sufficient for the C18b-mPEG750 double
shell but reverse-phase HPLC had to be applied for C18-mPEG350 and C19-mPEG350 to remove
residual diacid.
3.1.2. Synthesis of the CMS Architectures
Using hPG as a core molecule instead of its amino derivative not only avoids the potentially toxic








Scheme 1. Synthetic route of all ester-based CMS nanocarriers.
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The alcohol of bare hPG, however, features a lowered nucleophilicity in comparison to its aminated
counterpart. Therefore, a higher reactivity of the carboxylic group becomes necessary. Activation to
the acid chloride prior to the reaction with thionyl chloride led to the desired product (see Scheme 1).
The amounts of 0.8–2 eq. acid chloride-activated shell (depending on batch size) were used because of
its sensitivity towards water. Ultrafiltration compared to dialysis yielded purer compounds and the
molecular-weight cut-offs were between 3 kDa and 30 kDa in methanol, depending on the molecular
weight of the double-shell.
3.2. Degree of Functionalisation
In order to estimate the degree of functionalization, the molecular weights of all CMS were
determined by gel permeation chromatography (GPC) in DMF. All systems were as well analyzed
with NMR spectroscopy. The results are given in Table 1, the estimated error of the determination of
the DF by NMR is in the range of 10% (see Figure S2).
The molecular weights determined by GPC analysis were all in the same range. The degree of
functionalization (DF) was determined from 1H NMR by comparing the combined hPG/mPEG peak
to the signal of the aliphatic protons of the inner shell. The residual signal originated from core protons
and therefore the DF could be calculated using Equation (1) for CMS nanocarrier with an inner shell
length of 12 to 19 carbon atoms and Equation (2) for CMS-E18b.
DF =
5






The Mn of CMS nanocarriers and hPG were used for calculating the DF values from the GPC data,
and are all stated in Table S1. The GPC data indicates that all nanocarriers were defined (PDI < 2) and
of comparable molecular weights (Mn ~40 kDa). The GPC-based DF values were smaller than the ones
calculated from NMR spectra. This was due to the comparison to a linear standard (polystyrene) in
the GPC analysis that made the nanocarriers appear smaller, which is why the estimation via NMR is
more realistic.
Table 1. Estimation of the degree of functionalization (NMR) and GPC analytical data.
Compound Mn [kDa] PDI DF (NMR)
CMS-A18 41.8 1.85 65%
CMS-E12 32.2 1.31 88%
CMS-E15 43.1 1.79 90%
CMS-E18 34.9 1.41 88%
CMS-E19 32.3 1.31 75%
CMS-E18b 33.3 1.68 69%
3.3. DSC Measurements
Differential scanning calorimetrywas used to analyze the carriers regarding their phase-separation
and thermal transitions (Figure 2). All carriers except CMS-E18b and CMS-E12 exhibited two peaks.
Each of those peaks represents a segregated phase. The calorigrams of CMS-E18b and CMS-E12 only
showed one peak. Possible reasons for this include that no phase segregation took place in these
carriers or that the melting point (Tm) of the aliphatic phase was too close to the Tm of the mPEG
phase to result in separated peaks. The mPEG phase exhibited a Tm in the −20 to −10 ◦C region for
all carriers, which was in accordance with the melting point of mPEG350 (−8 ◦C) [27]. The second
peak represents the hydrophobic domain and proves phase-segregation. The temperature at which
this transition occurred reflects the interaction between chains in the phase that needs to be overcome
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for a less ordered state. Comparing CMS-E12, CMS-E15, CMS-E18, and CMS-E19, this Tm increases
as expected with higher chain lengths. Surprisingly, there is a significant step between CMS-E18 and
CMS-E19 of 26.8 ◦C with a difference of an inner chain length of only one methylene group. This
unexpectedly high Tm also influences other properties of the unimolecular micelle. While all other
CMS nanocarriers are highly soluble in water, the solubility of CMS-E19 at RT is only 60 mg·L−1.
At temperatures around 60 ◦C, it exceeds 5 mg mL−1, which is why the loading experiments were also





Figure 2. DSC measurements of CMS nanocarriers. Samples have been heated to 85 ◦C to erase any
thermal history. Graphs show second heating at 5 ◦C min−1.
3.4. DLS Analysis of Loaded and Unloaded CMS Nanocarriers
DLS analysis was applied to estimate hydrodynamic diameters in polar solvents and aggregation
phenomena upon loading in water. The two pharmacophores dexamethasone and tacrolimus were
chosen for two reasons: First, they are both commonly used in the therapy of inflammatory skin
diseases. Secondly, they are very different on a molecular level. While dexamethasone is a small
molecule and exhibits a rigid structure, tacrolimus features a relatively high molecular weight and
dynamic conformal changes. Table S2 summarizes the number-averaged results in methanol, which
reflect well the sizes of the unimolecular micelles. In water, the nanocarriers readily aggregated into
smaller and bigger aggregates, which was not the case for methanol. The hydrodynamic diameters
of ester-based nanocarriers were all in the range of 5 to 10 nm, which was expected for unimolecular
micelles and classifies them as nano-scale objects.
As the intensity-based distribution of a DLS measurement focuses more on larger particles in
suspension, the abundance of larger aggregates becomes visible. At the concentration of 5 mg mL−1,
DLS data (Table 2) indicated the formation of small aggregates even without a guest molecule. This was
in accordance to the findings published by Rabe et al. that suggested that CMS-A18 formed aggregates
of around eight unimers [28]. The next generation ester-based nanocarriers showed comparable sizes
that suggest a similar trend towards aggregates at higher concentrations.
When loaded with a hydrophobic guest molecule, the tendency towards aggregation increased.
The smaller aggregates disappeared and the larger colloidal structures became more predominant
in the DLS spectra, which is in accordance with previously published data [15,18]. These results
suggest bridging of two or more unimolecular micelles by a hydrophobic drug molecule, similar to the
formation of hydrophobic patches that drove aggregation. Tacrolimus-loaded CMS-A18 was the only
exception to this trend, but it also featured one of the lowest loading capacities. The ζ-potential of all
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carriers were approximately neutral. Thus, electrostatic interactions are assumed to play a minor role
in the aggregation phenomena.
Table 2. Intensity-based hydrodynamic diameters of unloaded and loaded CMS nanocarriers and the ζ
potential of unloaded CMS nanocarriers. Samples had a concentration of 5 g·mL−1 polymer and were
measured at 25 ◦C. Experiments were performed in triplicates.
Compound
Unloaded Tacrolimus-Loaded Dexamethasone-Loaded ζ Potential
d [nm] d [nm] d [nm] [mV]
CMS-A18
15 (81%) 19 (5%)
32 0.07 ± 0.09210 (19%) 204 (95%)
CMS-E12
14 (48%) 14 (5%) 63 (10%)
−1.27 ± 1.04134 (52%) 215 (95%) 361 (90%)
CMS-E15
15 (23%) 16 (10%) 16 (9%)
0.01 ± 0.06138 (77%) 208 (90%) 270 (91%)
CMS-E18 37
18 (15%) 24 (25%)
−5.9 ± 0.7224 (85%) 272 (74%)
CMS-E19 * 216 364
47 (9%)
0.01 ± 0.03329 (91%)
CMS-E18b 76 123 121 −0.003 ± 0.06
* Measured at 60 ◦C.
3.5. Loading Capacities of Dexamethasone and Tacrolimus
The loading capacity (LC) of a carrier depends on the method and on the guest molecule
encapsulated in it. It is defined as the solubilized mass concentration of a guest compared to the mass





To determine LC, dexamethasone and tacrolimus were encapsulated via the film uptake method,
respectively. Fifty weight percent of the drug was dissolved in ethanol and the solvent was removed to
form a film. Then, the stock solution of the carrier in water was added and the suspension stirred for
22 h. After removal of the non-solubilized drug by filtration, the guest concentration was measured
by HPLC and the loading capacities calculated (see Equation (3)). Dexamethasone, a rather small
hydrophobic drug, can be encapsulated in all carriers (except for CMS-E19) with reasonable loading
capacities (Figure 3 and Table S4 for numerical values). Comparing CMS-E12, CMS-E15, CMS-E18,
and CMS-E19, one could find no clear trend between the chain length and the melting points obtained
from DSC measurements (see Figure S3). The higher the hydrophobic interactions between the carriers,
the lower were the interactions between drug and carrier. CMS-A18 and CMS-E18 differ only in
the bond between core and inner shell (amide versus ester bond). Amide bonds are known to form
hydrogen bonds and can induce highly ordered structures. This seems to be beneficial for a rigid
and planar drug such as dexamethasone. Furthermore, hydrogen bonds can be formed between
the core amide and hydroxyl groups of the guest molecule. These two factors resulted in an overall
higher loading capacity for dexamethasone in CMS-A18 compared to CMS-E18. Due to its branching
and structural diversity, CMS-E18b exhibited the least ordered hydrophobic segment, which also
resulted in a low Tm (see Figure 2). Apparently, the low degree of order for the hydrophobic chains
was not beneficial compared to the unbranched system CMS-E18 for encapsulation of the rigid
drug dexamethasone.
Employing the same method and a similar, HPLC-based analysis, the LCs for tacrolimus were
determined as well (see Figure 4 and Table S4 for numerical values). Among the carrier architectures
in discussion, there was a clear maximum at the inner shell length of 15 carbon atoms. This was
39
Polymers 2017, 9, 316 12 of 17
due to two effects. Along the carriers, CMS-E12–CMS-E15–CMS-E18, the increasing hydrophobic
interactions impeded higher drug loading such as in the case of dexamethasone. Additionally, the
sterically demanding molecule tacrolimus required a minimum size of hydrophobic segments, which
was too small in the case of CMS-E12. Hence, the optimum size in this row was 15 carbon atoms.
Comparing CMS-A18 to CMS-E18, exchanging the ester bonds to amide bonds had a tremendous
effect on the LC. The rather rigid segments of C18 chains in the amide-functionalized carrier impaired
efficient encapsulation of the flexible and large macrocycle tacrolimus. This did not seem to be the case
for CMS-E18. Three to fourfold higher LCs were measured for this system. CMS-E18b, which featured
the least ordered hydrophobic segment, had a similar LC to CMS-E18. The branching of the inner shell
and a longer PEG outer shell was not beneficial for the encapsulation of tacrolimus.
Figure 3. Loading capacities of the investigated carrier systems. Encapsulation was performed with
the film uptake method, n = 3, * performed at 60 ◦C.
Figure 4. Loading capacities of tacrolimus in the examined carrier systems vs. the Tm values of the
inner shell. Encapsulation was done with the film-uptake method, n = 3, error bars indicate standard
deviation, * performed at 60 ◦C.
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3.6. Enzymatic Degradation of Unloaded Carriers
The rate at which the carrier is degraded enzymatically was determined by adding a lipase to
a solution of nanotransporter in PBS and taking samples at certain time points. The commercially
available lipase from Rhizomucor miehei was chosen because of the resemblance of the inner shell
building blocks to fatty acids, its native substrate. The samples were lyophilized, redissolved in
DMSO-d6 and analyzed in 1H NMR. The α-protons and the methylene group adjacent to the ester
group on the PEG side were tracked in the 1H NMR spectra (the protocol was adapted from a method
published earlier by our group) [29]. The chemical shift of the α-protons depends on whether the
carboxylic acid was esterified or not. At t = 0, there were only the peak at 2.23 ppm, which represented
the 4 esterified α-protons, as well as the peak at 4.07 ppm, that originated from the two PEG protons
adjacent to the ester bond. These signals indicated ester bonds only. Upon degradation, the peak
at 4.07 ppm decreased and two new peaks appeared and started to grow over time in the NMR
spectrum (see Figure S4). One was a triplet at 2.17 ppm and the other one was a broad signal at
2.12 ppm. Both represent non-esterified α-protons, the triplet originated from a non-carrier bound
carboxylic functionality, while the broad signal can be attributed to a carboxylic function still bound to
the nanocarrier architecture. Hence, ester cleavage is reflected in the signals of the α-protons. Whether
the inter-shell ester or the core-ester is cleaved (Figure 5), can be determined by tracking the PEG
protons at 4.07 ppm. By cleavage at the inter-shell site, this signal will lose intensity. The results of this
analysis are plotted in Figure 6 and complement a previous study examining the degradation of the
nanocarriers by skin lysate [22]. The graph shows degradation of more than 70% of all ester groups for
all carriers after six days. Since the used method not only allows one to follow the total cleavage of all
ester groups but also the individual monitoring of cleavage sites, one can see which bond was cleaved
first (Figures 5 and 6 and Figure S5).
Surprisingly, the core ester bond was cleaved at a comparable rate as the inter-shell ester.
In the first 24 h, almost no inter-shell esters cleaved. The reaction rate was very similar after that.
The simultaneous cleavage of core and inter-shell ester showed that an enzyme of a molecular weight
of 29.6 kDa still could enter the spherical particle and catalyze ester cleavage, which indicated the high
flexibility of the CMS nanocarriers. In contrast, no cleavage could be observed for the amide-based
CMS nanotransporters under the same conditions (see Figure S6). This was surprising because the
CMS-A18 also has esters as the linkage of the diacid with the mPEG and hence ester cleavage should







Figure 5. Different cases of ester cleavage. Depending on the site of cleavage, either the double shell
(a) or the PEG-chain (b) is cleaved off.
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Figure 6. Comparison of the degree of hydrolysis for the ester bonds by lipase from Rhizomucor miehei
as determined by NMR (DMSO-d6), n = 1.
3.7. Release Mediated by Enzymatic Cleavage
The guest molecule is encapsulated in the CMS nanocarrier by physical entrapment, which leads
to its solubilization. Its release is realized by diffusion out of the nanoparticle into the surrounding
medium. A second mechanism is the degradation of the carrier in a confined volume upon which it
will lose its ability to solubilize hydrophobic drugs. In order to determine the kinetics of this second
mechanism, the particles were loaded with dexamethasone and enzymatically degraded. The released
drug precipitated, and was separated by centrifugation. The reduced drug content of the supernatant
was measured by HPLC to determine the remaining solubilizing effect of the partially degraded carrier.
After resuspension, the procedure was repeated at different time points. In this procedure, we focused
on the best performing carrier systems, CMS-E12, CMS-E15 and CMS-E18. In order to only determine
the surplus value of the CMS nanotransporter, from each value, c(sup) and ct=0(sup), the natural
solubility of Dexamethasone, csat(Dx), was deducted (Equation (4)). Then, the ratio of each value
c(sup) to its initial value ct=0(sup) was calculated and subtracted from 1 to normalize the graphs.






This protocol was carried out with double carrier concentration to increase the effect but the
carrier/enzyme ratio was kept identical to get a comparable time scale in which the degradation took
place. Figure 7 indicates that all carriers underwent a rapid change in their transport properties. The
solubilization enhancing properties strongly diminished within a degradation time of one day. In the
same period, only around 3% of the payload was released in the UC and around 20% in seven days.
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Figure 7. Increase of drug release upon degradation in comparison to the untreated control (UC).
CMS nanocarrier concentration 10 mg·mL-1, n = 3.
4. Discussion
By introducing the ester linkage between core and inner shell of CMS nanocarriers, an easier
synthetic route was established. The synthesis was reduced to three synthetic steps as compared
to six for the amide-based system. The resulting CMS nanocarriers showed different aggregation
phenomena from its amide-functionalized counterpart. These properties were strongly linked to the
loading capacities of the carriers. While a short inner shell of 12 carbon atoms and amide bonds were
beneficial for encapsulation of the rigid molecule dexamethasone, the bulkier tacrolimus showed
a clear optimum at an inner shell chain length of 15 carbon atoms which was attached via an ester
linkage. Furthermore, ester-based carriers showed a high degree of enzymatic degradability. Hence,
this new class of ester-based CMS nanocarrier presented here combines optimized loading capacities
for the anti-inflammatory hydrophobic drugs dexamethasone and tacrolimus, easy synthesis, and
enzymatic degradability.
Supplementary Materials: Supplementary materials are available online at http://www.mdpi.com/2073-4360/
9/8/316/s1.
Acknowledgments: We acknowledge Pamela Winchester for proofreading the manuscript and thank Eike Mucha,
Maren Meurer, and Oliver Etzold for their support in the lab as well as Luisa Duque and Roland Bodmeier for
their help with the DSC measurements. We would also like to thank the Deutsche Forschungsgemeinschaft (DFG)
via SFB 1112 for the financial support.
Author Contributions: Michael L. Unbehauen and Rainer Haag conceived and designed the experiments; Michael
L. Unbehauen synthesized the nanocarriers CMS-E18, CMS-E19 and CMS-E18b and performed the experiments;
Michael L. Unbehauen analyzed the data; Emanuel Fleige, Florian Paulus and Sam Dylan Moré provided the
Nanocarriers CMS-E12, CMS-E15 and CMS-A18 and the performed GPC Analysis; Stefan Mecking and Brigitta
Schemmer contributed the C19 building block; and Michael L. Unbehauen wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
CMC Critical micellar concentration
CMS Core–multishell
CR Cumulative release
DDS Drug delivery system
DF Degree of functionalization
hPG Hyperbranched polyglycerol
43
Polymers 2017, 9, 316 16 of 17




1. Williams, A.C.; Barry, B.W. Penetration enhancers. Adv. Drug Deliv. Rev. 2012, 64, 128–137. [CrossRef]
2. Papakostas, D.; Rancan, F.; Sterry, W.; Blume-Peytavi, U.; Vogt, A. Nanoparticles in dermatology.
Arch. Dermatol. Res. 2011, 303, 533–550. [CrossRef] [PubMed]
3. Bolzinger, M.-A.; Briançon, S.; Pelletier, J.; Chevalier, Y. Penetration of drugs through skin, a complex
rate-controlling membrane. Curr. Opin. Colliod Interface Sci. 2012. [CrossRef]
4. Alves, M.P.; Scarrone, A.L.; Santos, M.; Pohlmann, A.R.; Guterres, S.S. Human skin penetration and
distribution of nimesulide from hydrophilic gels containing nanocarriers. Int. J. Pharm. 2007, 341, 215–220.
[CrossRef] [PubMed]
5. Alvarez-Román, R.; Naik, A.; Kalia, Y.N.; Guy, R.H.; Fessi, H. Enhancement of Topical Delivery from
Biodegradable Nanoparticles. Pharm. Res. 2004, 21, 1818–1825. [CrossRef] [PubMed]
6. Rancan, F.; Papakostas, D.; Hadam, S.; Hackbarth, S.; Delair, T.; Primard, C.; Verrier, B.; Sterry, W.;
Blume-Peytavi, U.; Vogt, A. Investigation of polylactic acid (PLA) nanoparticles as drug delivery systems for
local dermatotherapy. Pharm. Res. 2009, 26, 2027–2036. [CrossRef] [PubMed]
7. Patzelt, A.; Richter, H.; Knorr, F.; Schäfer, U.; Lehr, C.-M.; Dähne, L.; Sterry, W.; Lademann, J. Selective
follicular targeting by modification of the particle sizes. J. Control. Release 2011, 150, 45–48. [CrossRef]
[PubMed]
8. Shim, J.; Seok Kang, H.; Park, W.-S.; Han, S.-H.; Kim, J.; Chang, I.-S. Transdermal delivery of mixnoxidil with
block copolymer nanoparticles. J. Control. Release 2004, 97, 477–484. [CrossRef]
9. Newkome, G.R.; Moorefield, C.N.; Baker, G.R.; Saunders, M.J.; Grossman, S.H. Unimolecular Micelles.
Angew. Chem. Int. Ed. Engl. 1991, 30, 1178–1180. [CrossRef]
10. Jansen, J.F.; de Brabander-van den Berg, E.M.; Meijer, E.W. Encapsulation of guest molecules into a dendritic
box. Science 1994, 266, 1226–1229. [CrossRef] [PubMed]
11. Kurniasih, I.N.; Keilitz, J.; Haag, R. Dendritic nanocarriers based on hyperbranched polymers. Chem. Soc. Rev.
2015, 44, 4145–4164. [CrossRef] [PubMed]
12. Kataoka, K.; Harada, A.; Nagasaki, Y. Block copolymer micelles for drug delivery: Design, characterization
and biological significance. Adv. Drug Deliv. Rev. 2001, 47, 113–131. [CrossRef]
13. Prabaharan, M.; Grailer, J.J.; Pilla, S.; Steeber, D.A.; Gong, S. Amphiphilic Multi-Arm Block Copolymer
Based on Hyperbranched Polyester, Poly(L-lactide) and Poly(ethylene glycol) as a Drug Delivery Carrier.
Macromol. Biosci. 2009, 9, 515–524. [CrossRef] [PubMed]
14. Li, X.; Qian, Y.; Liu, T.; Hu, X.; Zhang, G.; You, Y.; Liu, S. Amphiphilic multiarm star block copolymer-based
multifunctional unimolecular micelles for cancer targeted drug delivery and MR imaging. Biomaterials 2011,
32, 6595–6605. [CrossRef] [PubMed]
15. Radowski, M.R.; Shukla, A.; von Berlepsch, H.; Böttcher, C.; Pickaert, G.; Rehage, H.; Haag, R.
Supramolecular aggregates of dendritic multishell architectures as universal nanocarriers. Angew. Chem. Int.
Ed. Engl. 2007, 46, 1265–1269. [CrossRef] [PubMed]
16. Küchler, S.; Radowski, M.R.; Blaschke, T.; Dathe, M.; Plendl, J.; Haag, R.; Schäfer-Korting, M.;
Kramer, K.D. Nanoparticles for skin penetration enhancement—A comparison of a dendritic
core-multishell-nanotransporter and solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 2009, 71, 243–250.
[CrossRef] [PubMed]
17. Quadir, M.A.; Radowski, M.R.; Kratz, F.; Licha, K.; Hauff, P.; Haag, R. Dendritic multishell architectures for
drug and dye transport. J. Control. Release 2008, 132, 289–294. [CrossRef] [PubMed]
18. Fleige, E.; Ziem, B.; Grabolle, M.; Haag, R.; Resch-Genger, U. Aggregation Phenomena of Host and Guest
upon the Loading of Dendritic Core-Multishell Nanoparticles with Solvatochromic Dyes. Macromolecules
2012, 45, 9452–9459. [CrossRef]
19. Weber, M.; Zoschke, C.; Sedighi, A.; Fleige, E.; Haag, R.; Schäfer-Korting, M. Free Energy Simulations
of Cargo-Carrier Interactions for Core-Multishell Nanotransporters. J. Nanomed. Nanotechnol. 2014, 5.
[CrossRef]
44
Polymers 2017, 9, 316 17 of 17
20. Zhu, Y.; Hazeldine, S.; Li, J.; Oupický, D. Dendritic polyglycerol with secondary amine shell as an efficient
gene delivery vector with reduced toxicity. Polym. Adv. Technol. 2014, 25, 940–947. [CrossRef]
21. Roller, S.; Zhou, H.; Haag, R. High-loading polyglycerol supported reagents for Mitsunobu- and
acylation-reactions and other useful polyglycerol derivatives. Mol. Divers. 2005, 9, 305–316. [CrossRef]
[PubMed]
22. Hönzke, S.; Gerecke, C.; Elpelt, A.; Zhang, N.; Unbehauen, M.; Kral, V.; Fleige, E.; Paulus, F.; Haag, R.;
Schäfer-Korting, M.; et al. Tailored dendritic core-multishell nanocarriers for efficient dermal drug delivery:
A systematic top-down approach from synthesis to preclinical testing. J. Control. Release 2016, 242, 50–63.
[CrossRef] [PubMed]
23. Stemp, F.; Quinzler, D.; Heckler, I.; Mecking, S. Long-Chain Linear C 19 and C 23 Monomers and
Polycondensates from Unsaturated Fatty Acid Esters. Macromolecules 2011, 4159–4166. [CrossRef]
24. Sunder, A.; Hanselmann, R.; Frey, H.; Mülhaupt, R. Controlled synthesis of hyperbranched polyglycerols by
ring-opening multibranching polymerization. Macromolecules 1999, 32, 4240–4246. [CrossRef]
25. Fulmer, G.R.; Miller, A.J.M.; Sherden, N.H.; Gottlieb, H.E.; Nudelman, A.; Stoltz, B.M.; Bercaw, J.E.;
Goldberg, K.I. NMR Chemical Shifts of Trace Impurities: Common Laboratory Solvents, Organics, and
Gases in Deuterated Solvents Relevant to the Organometallic Chemist. Organometallics 2010, 29, 2176–2179.
[CrossRef]
26. Brundiek, H.; Sa, S.; Evitt, A.; Kourist, R.; Bornscheuer, U.T. The short form of the recombinant CAL-A-type
lipase UM03410 from the smut fungus Ustilago maydis exhibits an inherent trans-fatty acid selectivity.
Appl. Microbiol. Biotechnol. 2012, 94, 141–150. [CrossRef] [PubMed]
27. Chauvin, C.; Ollivrin, X.; Alloina, F.; Lenest, J.-F.; Sanchez, J.-Y. Lithium salts based on oligoether sulfate
esters. Electrochim. Acta 2005, 50, 3843–3852. [CrossRef]
28. Rabe, C.; Fleige, E.; Vogtt, K.; Szekely, N.; Lindner, P.; Burchard, W.; Haag, R.; Ballauff, M. The multi-domain
nanoparticle structure of a universal core-multi-shell nanocarrier. Polymer 2014, 55, 6735–6742. [CrossRef]
29. Kurniasih, I.N.; Liang, H.; Kumar, S.; Mohr, A.; Sharma, S.K.; Rabe, J.P.; Haag, R. A bifunctional nanocarrier
based on amphiphilic hyperbranched polyglycerol derivatives. J. Mater. Chem. B 2013, 1, 3569. [CrossRef]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
45
 - 1 - 
Supporting Information 
Biodegradable Core-Multishell Nanocarriers: 
Influence of Inner Shell Structure on the 
Encapsulation Behavior of Dexamethasone and 
Tacrolimus 
Michael L. Unbehauen 1, Emanuel Fleige 1,2, Florian Paulus 1,2, Brigitta Schemmer 3, 
Stefan Mecking 3, Sam Dylan Moré 2 and Rainer Haag 1,* 
1 Freie Universität Berlin, Institute for Chemistry and Biochemistry, Takustraße 3, 14195 Berlin, Germany 
2 DendroPharm GmbH, Arnimallee 14, 14195 Berlin, Germany 
3 Chemical Materials Science, Department of Chemistry, University of Konstanz, Universitätsstraße 10, 78467 
Konstanz, Germany 
* Correspondence: haag@chemie.fu-berlin.de; Tel.: +49-30-838-52633
1. Material and Methods
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The compound C18b is a mixture of different isomers of the dimeric fraction of the product EMPOL 
1026 from Cognis. The dimeric fraction was isolated by column chromatography with hexane/ethyl 
acetate on acidified (acetic acid) silica. The dimeric fraction comprises of the compounds that are given 
in Scheme S1 and its isomers. 
2. Degree of Functionalization
Table S1. Estimation of the degree of functionalization from GPC analytical data based on Mw. 







2.1. Calculation of DF via NMR 
All signals between 4.48 ppm and 3.32 ppm and an additional peak at 5.20 ppm can be attributed 
to all methylene and methine protons of hPG (Figure S1, a) and is partially overlaid with peaks assigned 
to the PEG backbone. (Figure S1, e,f,g) The aliphatic signal at 1.34 ppm, which has 18 protons (d), is 
needed to estimate the fraction that is assigned to the hPG backbone (a).  
Per glycerol unit, the signal (a) originates from 5 protons of the hPG backbone and, depending on 
the degree of functionalization (DF), another 28.8 protons are in position e + f at the PEG backbone and 
additional 3 at position g (Equation S1 and S2). The signal of the 18 protons in (d) also depends on the 
DF (Equation S3). 
Having established these relations (S1-3), the focus is now on the single double-shell chain. Scaling 
the peak (d) ppm to 18, one can now calculate the relation between DF and 𝜎𝑎,𝑒,𝑓,𝑔 (Equation S4) using 
Equation S2 and S3. This equation is then simplified to Equation S5 and later solved for DF to yield 
Equation S6, which now can be used to calculate DF from 𝜎𝑎,𝑒,𝑓,𝑔  after having set 𝜎𝑑  to 18. This 
procedure works equally for CMS-A18, for CMS-E12 𝜎𝑑 set to 12, for CMS-E18 to 24, and for CMS-E19 
to 26.  An adapted form of this equation (Equation S7) was used to calculate DF of CMS-E18b. In this 
case, the methoxy peak at 3.36 ppm was set at 3. 
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Figure S1. Exemplary chemical structure of a functionalized glycerol unit (top) and the respective 1H-
NMR spectrum (bottom) of CMS-E12. 
 𝜎𝑎,𝑒,𝑓,𝑔 = 5 + 7.2 ∙ 4 ∙ 𝐷𝐹 + 3 ∙ 𝐷𝐹 (S1) 𝜎𝑎,𝑒,𝑓,𝑔 = 5 + 31.8 ∙ 𝐷𝐹 (S2) 𝜎𝑑 = 18 ∙ 𝐷𝐹 (S3) 
𝜎𝑎,𝑒,𝑓,𝑔 = 𝜎𝑎,𝑒,𝑓,𝑔𝜎𝑑 ∙ 18 = 5 + 31.8 ∙ 𝐷𝐹𝐷𝐹  (S4) 
𝜎𝑎,𝑒,𝑓,𝑔 = 5𝐷𝐹 + 31.8 (S5) 
𝐷𝐹 = 5𝜎𝑎,𝑒,𝑓,𝑔 − 31.8 (S6) 
𝐷𝐹 = 5𝜎𝑔 − 63.2 (S7) 
2.2. Accuracy of the NMR experiment 
Assuming an average measurement error (ME) of 3 %, the deviation for the measured DF was 
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and S6 and estimates the deviation by converting a theoretical DF into an NMR integral σ, adding or 
subtracting the measuring error (ME) and converting it back. Equation S8 is valid for CMS nanocarriers 
using mPEG350, S9 for CMS-E18b. As depicted in Fig. S2, the range of error increases with higher DF, 
leading to a rather rough estimation for highly functionalized CMS architectures. 𝐷𝐹𝑚𝑖𝑛/𝑚𝑎𝑥 = 5( 5𝐷𝐹𝑟𝑒𝑎𝑙 + 31.8) ∙ (1 ±𝑀𝐸) − 31.8 (S8) 𝐷𝐹𝑚𝑖𝑛/𝑚𝑎𝑥 = 5( 5𝐷𝐹𝑟𝑒𝑎𝑙 + 63.2) ∙ (1 ±𝑀𝐸) − 63.2 (S9) 
Figure S2. Estimated range of deviation (red) based on a measuring error of the NMR-experiment of 3% 
for CMS with mPEG350 (left) and mPEG750 (right). 
 
3. Hydrodynamic sizes 
Table S2. Hydrodynamic diameters of CMS in methanol determined by DLS. 
Compound  
Size (DLS, diameter, methanol, 
number) 
CMS-A18  6.4 
CMS-E12  8.5 
CMS-E15  5.9 
CMS-E18  8.6 
CMS-E19  6.9 










































 - 5 - 
 
 
Table S3. Hydrodynamic diameters of CMS water, before and after filtration, and in PBS determined 
by DLS, percentage of signal in brackets. 
Compound Size before filtration Size after filtration Size after addition of PBS 
CMS-E12 
14.5 nm (43%) 
228 nm (54%) 
13.8 nm (48%) 
143 nm (52%) 
14.8 nm (48%) 
143 nm (48%) 
CMS-E15 
14.1 nm (27%) 
113 nm (73%) 
16.3 nm (31%) 
145 nm (69%) 
20.6 nm (36%) 
154 nm (64%) 
CMS-E18 42.3 nm 39.2 nm 39.6 nm 
The hydrodynamic diameter was measured before and after filtration with a 450 nm RC filter and 
after the dissolution of PBS salt. The sizes and populations widely remained the same, only in CMS-E12 
the aggregates’ diameters decreased.  
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4. Loading Capacity vs. Tm of the inner shell 
 
 
Figure S4. Loading capacities of the investigated carrier architectures for dexamethasone (top) and 
tacrolimus (bottom) plotted against the melting temperature of their respective inner shell. No 





























































Tm (inner shell) [°C]
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CMS-A18 3.0 ± 0.7 0.26 ± 0.1 
CMS-E12 2.8 ± 0.5 1.1 ± 0.2 
CMS-E15 2.5 ± 0.4 1.7 ± 0.1 
CMS-E18 1.7 ± 0.5 1.16 ± 0.1 
CMS-E19* 0.6 ± 0.1 0.07 ± 0.1 
CMS-E18b 2.1 ± 0.3 1.3 ± 0.3 
*measured at 60°C 
5. Enzymatic degradation of CMS-E 
 
Figure S4. Relevant NMR signals for determining the rate of degradation in DMSO-d6: The signal at 
4.07 ppm vanishes over time, indicating a cleavage of the inter-shell ester. The signal at 2.23 decreases 
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upon any ester cleavage and reappears either as a triplet at 2.18 ppm (cleavage of the inter-shell ester) or 





Figure S5. Degree of cleavage of total ester bonds (blue) and inter-shell ester bonds of CMS-E15 as 
determined by NMR (DMSO-d6). 
 
6. Enzymatic degradation of CMS-A18 
 
 
Figure S6. Comparison of the relevant peaks to determine the degree of degradation in DMSO-d6 at the 


















total esters Inter-shell esters
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the triplet at 2.18 ppm to the α-protons of the acid. The broad peak between 2.12 ppm and 1.97 ppm is 
assigned to the amide α-protons and is overlapped by an impurity at 2.08 ppm. There is no decrease of 
the amide or ester peaks over time in favor of the signal of the acid protons over time. 
7. Release mediated by enzymatic cleavage 
 
Figure S7. Cumulative Release (CR) of the absolute amounts of dexamethasone from the solutions of 
loaded carriers (polymer concentration 10 g/L) in comparison to the untreated control (UC) without 
enzyme, n=3.  
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3.2 Tailored dendritic core-multishell nanocarriers for efficient dermal drug 
delivery: A systematic top-down approach from synthesis to preclinical 
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innovative drug delivery system for the application at the oral mucosa 
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3.4 Anionic Core-multishell Nanocarriers for the Delivery of Analgesics to 
Inflamed Tissue 
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U 50,488H (U50) is a κ-opioid receptor agonist exerting effective analgesia in animal pain 
models. Yet, side effects such as sedation and depression-like symptoms mediated in the brain 
limit its therapeutic potential. In this study, we present tailor-made core-multishell nanocarriers 
containing U50 that, despite their small size, exhibit a pH-dependent retention effect via non-
covalent interactions with the drug. The nanocarriers and their non-functionalized counterparts 
are characterized regarding their release properties in vitro, including a theoretical modeling of 
the release parameters. Finally, the U50-containing nanocarriers are tested in vivo in a rat model 
of inflammatory pain. 
1. Introduction 
Pain is the most common symptom for which patients seek medical treatment and it is a health 
problem of high socio-economic importance.[1,2] Current pain management relies on 
nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. NSAIDs are often ineffective in 
severe pain and limited by serious side effects, including gastrointestinal ulcers and bleeding, 
stroke and myocardial infarction.[3,4] Opioids are the strongest painkillers, which exert their 
action via three types of opioid receptors, µ, δ, and κ. The most widely used opioids include 




produce side effects such as sedation, constipation, respiratory depression, euphoria, misuse, 
and addiction, which resulted in the opioid crisis.[5–7] In contrast, κ-opioid receptor agonists 
lack the abuse potential of µ-opioids, which made them promising candidates for pain 
treatment. A prototypic κ-receptor selective agonist is U 50,488H (U50), which has been 
shown to exert effective analgesia in animal pain models. Nevertheless, due to the permeation 
of the blood-brain barrier (BBB), U50 and related compounds can produce psychotic effects 
(e.g., disorientation, confusion, hallucinations), sedation, and depression-like symptoms, 
mediated by κ-receptors in the brain.[8,9] 
Importantly, apart from the brain, opioid receptors are also expressed in peripheral sensory 
neurons (nociceptors) innervating peripheral tissue (skin, muscles, joints, bones, viscera), and 
majority of painful syndromes are associated with such tissue inflammation, including 
postoperative, arthritis, neuropathic, and cancer pain. Under such conditions, the synthesis, 
signaling and agonist accessibility of opioid receptors in peripheral sensory neurons is 
increased. Additionally, functional opioid receptors are expressed in immune cells 
accumulating in injured tissue. As a result, locally applied opioids, including U50, in small, 
systemically inactive doses have been shown to produce effective analgesia devoid of 
centrally-mediated side effects.[10–15]  Previous attempts to achieve the restriction of κ-agonists 
to peripheral opioid receptors included incorporation of quaternary or non-quaternary polar 
hydrophilic structures, moderate hydrophilic substituents, or amphiphilic molecules. However, 
these modifications often decreased agonist affinity to receptors, which required the use of 
relatively high doses and did not warrant complete BBB impermeability, and paradoxically 
enhanced pain in some cases.[8,13,16] 
Particularly in recent years, formulations such as nanoparticles, nanocapsules, or nanofibers 
have gained much interest.[17,18] Materials used for these structures are usually polyesters like 
PCL, PLA, or PLGA, and contain the local anesthetic either incorporated directly, or, in the 
case of the nanocapsules, dissolved in an oily core surrounded by the polymer.[19–21] Thus, the 
mechanism of action usually involves erosion of the matrix material and diffusion of the drug 
out of the material.[22] Along with these nanostructures, liposomal formulations have been 
tested for the delivery of anesthetics. A structure inspired by the liposome is the so-called core-
multishell (CMS) nanocarrier previously published by our group,[23] which consists of a 
hyperbranched polymer as a core to which amphiphilic chains are attached. This architecture 
has been proven to encapsulate and solubilize guest molecules and other nanoparticles in 




transport of model drugs into skin and for the accumulation of the dye ITCC in tumor tissue 
via the enhanced permeability and retention (EPR) effect.[25,26] In the past years, this parent 
structure has been altered to include new materials and types of bonds used to construct CMS 
nanocarriers.[27–29] For example, hyperbranched polyglycerol and oligoesters were used in this 
architecture to reduce toxicity and enable cleavability and biodegradability. Furthermore, the 
CMS nanocarriers were subject to simulations regarding its structure, aggregation behavior, 
and release kinetics.[30,31] Also, the inner shell has been modified to transport copper ions across 
the BBB.[32] Similar to this approach, ionic interactions can be used to bind the pharmacophore 
to a nanoparticle. Examples here are photosensitizer or cis-platin-loaded PMMA nanoparticles 
and antioxidants loaded into functionalized hPG.[33–35]  
In this paper, we describe the development of two nanocarrier architectures (see Figure 1) with 
a pH-sensitive binding patch suitable for the interaction with U50 based on ionic interactions, 
hydrogen bonds, and π-π stacking. The major goal was to obtain a U50-containing nanocarrier, 
which following intravenous (i.v.) injection produces analgesia exclusively in peripheral 
inflamed tissue. Importantly, inflammation is associated with angiogenesis, enhanced 
permeability of the vascular endothelium, and local tissue acidosis (low pH).[36,37] Thus, the 
rationale was that due to high molecular mass and pH-sensitivity, the U50-containing 
nanocarrier will not cross the BBB, but will be able to diffuse through the permeable vascular 
endothelium in inflamed tissue where in a pH-sensitive manner will liberate U50 to locally 
ameliorate pain. To this end, the potential of the patch-functionalized CMS (pCMS) 
nanocarriers were quantified regarding their loading capacity and retention which then was 
further analyzed in a mathematical model. Finally, the analgesic effects of the most promising 
U50-containing nanocarriers were evaluated in the clinically relevant model of inflammatory 





Figure 1. Schematic structure of the patch-functionalized core-multishell (pCMS) nanocarrier 
and the drug U50 in its protonated form. 
2. Experimental Section 
All chemicals were used as bought without any further purification. Polyethylene glycol 
monomethyl ether (mPEG) 350, (±)-trans-U-50488 methanesulfonate salt, N-Z-L-aspartic 
anhydride, N,N-diisopropylethylamine (DIPEA), methanol, and benzoylated dialysis tubing 
(2 kDa, 32 mm) were bought from Sigma-Aldrich, Munich, Germany. hPG (MW = 10 kDa), 
hPG-NH2 (MW = 10 kDa, 70% amines), and CMS-A were produced by previously published 
methods.[27,38,39] CMS-E (brand name DendroSol®) and 15-methoxy poly(ethylene glycol)-15-
oxo pentadecanoic acid (mPEG350-C15) were received from Dendropharm, Berlin, Germany. 
Dry pyridine and dry DMSO were bought from Acros, Geel, Belgium and pyridine stored 
over calcium hydride (Acros). Dry DCM was taken from a solvent purification system (SPS-
800) by MBRAUN (Stratham, NH, USA) and stored over a molecular sieve (4 Å, Roth). 
Acetonitrile HPLC gradient grade was bought from Fisher Scientific, Schwerthe, Germany. 
MilliQ water was taken from a Millipore Advantage A10 system (Merck) and thionyl chloride 
was purchased from Merck, Darmstadt, Germany. 
Isolation of U50: Isolation of free-base U50 was performed by dissolving the respective 
methanesulfonate salt in water and adding a few drops of conc. aqueous ammonia. After 
centrifugation (4000 RPM, 10 min, Biofuge Primo, Heraeus, Hanau, Germany), the 
supernatant was taken off and the colorless solid dried under low pressure (< 0.5·10-2 mbar) 
for several hours. The absence of methanesulfonate was proven via IR spectroscopy. 
NMR spectroscopy: NMR spectra were recorded either on a Jeol Eclipse 500 MHz (Tokyo, 




carbon NMR were recorded in ppm and were referenced to the indicated solvents.[40] NMR 
data were reported including chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m 
= multiplet), integration, and coupling constants (s) in Hertz (Hz). Multiplets (m) were reported 
over the range (ppm) in which they appeared in the spectrum. All spectra were recorded at 
300 K. 
Dynamic Light Scattering (DLS): For the determination of hydrodynamic sizes, dynamic light 
scattering (DLS) measurements were performed on a Malvern Zetasizer Nano (Herrenberg, 
Germany) equipped with a laser at 532 nm using backscattering mode (detector angle 173°). 
The samples were filtered through 0.45 μm-regenerated cellulose syringe filters prior to DLS 
measurement and 100 μL of the resulting solution added to a disposable micro-cuvette. 
Autocorrelation functions were analyzed using Zetasizer DTS software (Malvern, Herrenberg, 
Germany) to determine the size distribution by intensity or number. The fraction (%) indicates 
the proportion of measured size relative to the total signal scattered by the CMS nanocarriers. 
For the pH-dependent measurements, a titrator was used. The initial pH was 11 and it was 
titrated with 1 M HCl. Measurements were performed at 25 °C. 
Gel Permeation Chromatography: A Shimadzu (Kyoto, Japan) liquid chromatography (LC) 
system was employed for the gel permeation chromatography (GPC) measurements. Three 
PolarSil columns (PSS Polymer Standards Service GmbH, Germany; PolarSil 8 × 300 mm, 
100 Å, 1000 Å, 3000 Å with 5 μm particle size) and a refractive index detector (RI) were used 
to separate and analyze polymer samples. As the mobile phase DMF (0.3 wt% LiBr and 0.6 
wt% acetic acid) was used at a flow rate of 1 mL·min−1. Columns and RI detector were heated 
to 40 °C. The system was calibrated against polystyrene calibration standards (PSS, Germany). 
Samples were measured at a concentration of 10 mg·mL−1. LC solution software from 
Shimadzu was used for data analysis. 
Film Encapsulation Method: The film uptake method was chosen for the encapsulation 
procedure. To form a film, 50 wt% of U50 488 free base was dissolved in a vial and the solvent 
removed on a rotavap. A stock solution of the respective CMS nanocarrier (5 mg·mL−1) was 
filled onto the film and the suspension stirred for 22 h at room temperature. Excess guest was 
removed via filtration through a 450 nm regenerated cellulose syringe filter.  
HPLC Analysis: The concentration of U50 was determined via high performance liquid 
chromatography (HPLC, Fertigsäule 125x4mm, RSC-Gel C18ec, 5µm, R. Sauerbrey 




(35/65, v/v) using a UV detector set to λ = 232 nm. For the preparation of the sample, the 
samples were diluted 1:1 with a mixture of 70 vol% acetonitrile and 30 vol% phosphate buffer 
43.3 mM, pH 2.9. Therefore the final sample had a solvent composition equal to the eluent. 
Dialysis-based Release Kinetics: To obtain data for the release kinetics, 1 mL of a donor 
solution was filled inside a dialysis tube (Pur-A-Lyzer Maxi, MWCO 6000-8000 g mol-1), 
which was placed in a reaction tube filled with 20 mL of stirred acceptor solution. At time 
points of 0, 1, 2, 4, 8, 24, and 48 h, 175 µL of the acceptor solution were transferred into a 96-
well plate (UV-Star® half area, Greiner Bio-One, Germany). The concentration of U50 was 
determined in by UV-spectrometry in a plate reader (Tecan Infinite 200 PRO) at 232 nm using 
fresh acceptor solution as a blank. As acceptor media, phosphate buffer (pH 7.4) or acetate 
buffer (pH 5.5) was used, when indicated, sodium chloride was added. The donor solutions 
were prepared either by diluting the encapsulated U50 in several nanocarriers or by mixing 
solutions of U50 mesylate salt and the respective nanocarrier. The concentration of the drug 
was kept at 2.71 mM, which corresponds to 1 g L-1 mesylate salt. This resulted in nanocarrier 
concentrations of 5.5 g L-1 for CMS-E, pCMS-A and pCMS-E and 7.4 g L-1 for CMS-A. 
Synthesis of C18mPEG350 and NHS-C18-mPEG350: The synthesis and the activation of this 
double-shell building block was performed as already described by our group.[41] In brief, an 
excess of 1,18-octdecandioic acid and methyl-polyethyleneglycol with a MW of 350 were 
heated up to 180 °C under low pressure (0.5·10-2 mbar) for 2h. Then, the reaction mixture was 
purified by hot filtration from toluene and the crude product by HPLC. The product was then 
activated to its NHS-ester by reacting it with NHS and DCC in THF overnight with subsequent 
purification by filtration in DCM.  
Synthesis of pCMS-A: 10 mL of dry DMSO was added to hPG-NH2 (130 mg, 1.04 mmol, 
20 g L-1 stock solution in methanol) and the methanol was removed under low pressure 
(<0.5ּ·10-2 mbar) to give a clear, slightly yellow solution. DIPEA (47.6 mg, 62.7 µL) was added 
and the solution heated to 50°C. N-Z-L-aspartic anhydride (61.2 mg, 0.25 mmol) was dissolved 
in 5 mL of dry DMSO and added dropwise. The reaction was left at 50°C for 2 hours. A sample 
of 2.3 mL (hPG-NH-AA) was taken and dialyzed against water (1L, 3 changes of dialysate) 
and methanol (1L, 2 changes). Then the solvent was exchanged to D2O by repetitive partial 
removal of solvent, addition of D2O, and measurement of an NMR spectrum until the 





Then, NHS-C18-PEG350 (849 mg, 1.14 mmol) in 5 mL of dry DMSO was added and the 
reaction mixture stirred overnight. The next morning, the solution was dialyzed against 
methanol (4x2 L, 2 kDa). Then, the solvent was removed to yield a slightly brown film 
(456.2 mg, yield = 83%).  
 
1H NMR: hPG-NH-AA (500 MHz, D2O) 8.14 (m, -NH-CO-, 0.18H), 7.44 (m, aromat. H, 
0.9H), 5.17 (m, Ph-CH2-, 0.36H), 4.50-2.90 (hPG backbone, 5H), 2.88-2.43 (-OC-CHNR-CH2-
CO-, 0.36H); pCMS-A (700 MHz, methanol-d4, TMS): δ (ppm) = 8.13 (m, -NH-CO-, 0.7H), 
7.35 (m, aromat. H, 0.9H), 5.09 (s (br), Ph-CH2-, 0.36H), 4.21 (s, –CH2–OCO–, 1.04H), 4.56–
3.39 (m, mPEG repeating unit, hPG backbone and -OC-CHNR-CH2-CO-, 19.3H), 3.36 (s, –
O–CH3, 1.56H), 2.33 (m, 1.04H, –CH2–CONH–), 2.23 (m, 1.04H, –CH2–COO–), 1.61 (m, 
2.08H, –CH2–CH2–CO–), 1.31 (m, 12.48H, –(CH2)12–).  
13C NMR: hPG-NH-AA (176.09 MHz, D2O): δ (ppm) = 171.0, 129.3-127.5, 72.9-65.9; pCMS-
A (176.09 MHz, methanol-d4): δ (ppm) = 176.3, 175.2, 129.9-128.9, 73.0, 72.2-71.3, 70.2, 
64.6, 59.2, 37.3, 35.06, 31.4-30.0, 27.2, 26.2  
Synthesis of pCMS-E: hPG (67.3 mg, 0.91 mmol) was dried by dissolving it in 1 mL of dry 
pyridine in a Schlenk flask and removing the solvent under low pressure (0.5 ּ·10-2 mbar) three 
times. Then, it was dissolved in 10 mL of dry pyridine, and N-Z-L-aspartic anhydride (45.3 mg, 
0.18 mmol) was added. The solution was stirred overnight at RT. Then, 1 mL was taken and 
the solvent removed under low pressure. It was redissolved in deuterated methanol and an 
NMR sample was submitted to determine the degree of functionalization of the anchor 
molecule on the hPG core. A three-neck flask was then equipped with a reflux-cooler (center), 
an olive, and a septum. The olive was used for the additional cryotrap and a three-way faucet 
for ventilation in between. To the reflux cooler, a device with two faucets was attached, one 
connected to an Ar inlet, another one employed as an outlet leading to a gas washing bottle 
containing 1 M NaOH. In this setup, C15-mPEG350 (1035 mg, 1.66 mmol, previously dried 
under HV overnight) was dissolved in 3.5 mL of dry dichloromethane. Thionyl chloride 
(300 µL, 2.5 mmol) was then added at 0°C, the temperature kept for another 5 min and then 
refluxed for 1.5 hours. Thionyl chloride and dichloromethane were evaporated in vacuo and 
5 mL of dry DCM was added and the solution cooled to 0°C. Dry pyridine (6 mL) was added 
to the hPG and the solutions cooled down to 0°C. Upon rapid stirring, the diluted solution of 




solvent was evaporated and the crude product redissolved in 10 mL of methanol and 
subsequently dialyzed against methanol (3x2 L) yielding the product as a viscous oil 
(463.8 mg, 86% yield). 
1H NMR: hPG-NH-AA (500 MHz, methanol-d4) 7.35 (m, aromat. H, 0.9H), 5.10 (m, Ph-CH2-
, 0.36H), 4.70-3.4 (hPG backbone, -OOC-CHNR-CH2-COO-, 5.18H), 2.87 (m, -OC-CHNR-
CH2-CO-, 0.36H); pCMS-E (700 MHz, methanol-d4): δ (ppm) = 7.38 (m, aromat. H, 0.9H), 
5.12 (m, Ph-CH2-, 0.36H), 4.72-4.59, (m, -OOC-CHNR-CH2-COO-, 0.18H) 4.21 (s, –CH2–
OCO–, 1.62H), 4.50–3.39 (m, mPEG repeating unit, hPG backbone, 27.1H), 3.36 (s, –O–CH3, 
2.43H), 3.04-2.81 (m, -OOC-CHNR-CH2-COO-, 9.36H) 2.34 (m, 1.62H, –CH2–COO–), 1.62 
(m, 3.24H, –CH2–CH2–CO–), 1.32 (m, 14.6H, –(CH2)9–).  
13C NMR: hPG-AA (125.77 MHz, methanol-d4): δ (ppm) = 129.8-128.6, 74.3-72.0; pCMS-A 
(176.09 MHz, methanol-d4): δ (ppm) = 175.1, 174.5, 129.7,129.2, 73.0, 71.6, 71.4, 70.2, 64.6, 
59.2, 35.1, 31.3-30.1, 26.2. 
Animals: All experiments were approved by the State animal care committee (Landesamt für 
Gesundheit und Soziales, Berlin) and performed according to the ARRIVE guidelines.[42] Male 
Wistar rats (250-300 g; Janvier Laboratories, France) were kept on a 12 h light/dark schedule, 
in groups of two in cages lined with ground corncob bedding, with free access to standard 
laboratory food and tap water. Room temperature was 22 ± 0.5°C and humidity 60-65%. Rats 
were handled once per day for 1-2 min, starting 4 days prior to experiments. After completion 
of experiments, animals were killed with an overdose of isoflurane (AbbVie, Germany). All 
efforts were made to minimize animal numbers and their suffering. 
Inflammatory Pain Model: Rats received an intraplantar (i.pl.) injection of a complete Freund’s 
adjuvant (CFA; 150 µl; Calbiochem, La Jolla, CA, USA) into the right hind paw under brief 
isoflurane anesthesia.[43] Experiments were performed at 4 days after inoculation with CFA. 
Mechanical Hyperalgesia (Paw Pressure Test): Rats were gently restrained under paper 
wadding and incremental pressure was applied via a wedge-shaped, blunt piston onto the dorsal 
surface of the hind paws by means of an automated gauge (Ugo Basile, Comerio, Italy), as 
previously.[37,44] The paw pressure threshold (cut-off at 250 g) required to elicit paw withdrawal 
was determined by averaging three consecutive trials separated by 15-s intervals. The sequence 




Drugs and Experimental Plan: Rats received injection (1 ml) into the tail vein of U50 (1-10 
mg kg-1), U50@CMS-E and U50@pCMS-E (both at 5-50 mg kg-1 polymer and 1-10 mg kg-1 
U50) under brief, general isoflurane anaesthesia. U50 was dissolved in sterile water, whereas 
U50@CMS-E and U50@pCMS-E were dissolved in PBS. Control groups were treated with 
empty (without U50) CMS-E or pCMS-E (both at 50 mg kg-1, i.e., equivalent of carrier 
containing 10 mg kg-1 U50) dissolved in PBS. To obtain final concentrations, all substances 
were diluted with 0.9% NaCl. Each group consisted of 8 rats. To reduce the number of animals, 
one control group was used for all treatments, which consisted of four rats treated with empty 
CMS-E and the other four rats with empty pCMS-E. There were no differences between the 
two treatments. Nociceptive thresholds were evaluated before and 10-60 min following 
injections. The doses of all agonists were determined in pilot experiments. The experimenter 
was blind to the drugs and their doses. A colleague not involved in experiments prepared each 
substance/dose in coded, separate vials (one per animal), which allowed randomization and 
blinding. The codes were broken after experiment completion. 
Statistical Analyses: For in vivo behavioral experiments, the animal numbers were estimated a 
priori using the G*Power 3.1.2 program, under consideration of α of 5%, power of 80%, 
variance of 25%, and the biologically relevant difference of 50%, which resulted in 8 animals 
per group. The data are expressed in raw values and AUC, and were assessed for normal 
distribution and equal variances by the D’Agostino-Pearson test. Two-sample comparisons 
were made using Wilcoxon test. Two-way repeated measures analysis of variance (ANOVA) 
and the Bonferroni test were used to compare two groups over time. The AUC values were 
obtained by calculating the area between the X-axis and the curve of the PPT time course from 
the baseline to 60 min after each treatment (control, and each dose of U50, U50+CMS-E, and 
U50+pCMS-E). The AUC data were analyzed by Kruskal-Wallis one-way ANOVA followed 
by the Dunn’s test.  Differences were considered significant if P < 0.05. Prism 5 (GraphPad, 
San Diego, USA) was used for all statistical tests and all data were expressed as means ± 
standard error of the mean (SEM).  
3. Results 
3.1. Synthesis of the functionalized nanocarriers 
To obtain modified CMS nanocarriers, the syntheses of two previously published CMS 
nanocarriers were modified (See Scheme 1).[27,41] In the initial syntheses, the diacid was reacted 
first with the PEG outer shell before the double shell was attached to the core. Into this strategy, 




functionalized with a Z-protected aspartic acid. In the case of pCMS-E, this could be achieved 
via the addition of the respective anhydride to hPG in pyridine. For the amide-based 
nanotransporter pCMS-A, a zwitterionic nanoparticle with a low solubility was the result of 
this functionalization. To prevent precipitation, the non-nucleophilic base 
diisopropylethylamine (DIPEA) was added and the temperature increased to 50 °C. DIPEA 
acted as a proton interceptor and ensured the negative charge of the functionalized core as well 
as the nucleophilicity of the amine functions, which was necessary for the subsequent reaction 
with the activated NHS-ester shell. 
 
Scheme 1. Synthesis of aspartic acid-modified nanocarriers. 
The degree of functionalization (DF) was determined via the quantitative analysis of 1H-NMR 
integrals with the typical accuracy in the range of 5%. In the case of the unfunctionalized CMS-
nanocarriers, this was done by comparing the aliphatic signal of the inner shell to the combined 
signal of the PEG/hPG-backbone as previously described.[45] In the case of pCMS, the DF for 
the anchor molecule AA was calculated by first relating the signals assigned to the aromatic 




aromatic integral was used as a reference for the signal of the aliphatic protons in the inner 
shell. The obtained values are compiled in Table 1. All the carriers exhibited a high degree of 
total functionalization while the percentage to which the aspartic acid was attached was equal 
in both functionalized carriers. The Mn was determined by GPC analysis against a linear 
standard. This comparison leads to a smaller molecular mass of the CMS nanotransporters than 
expected from the NMR data. 
Table 1. Degree of functionalization determined by NMR spectroscopy and molecular weights 
determined by GPC analysis. 
Nanocarrier DF AA DF shell DF total Mn PDI 
CMS-E - 90% 90% 43.1 1.8 
pCMS-E 18% 81% 99% 19.9 1.5 
CMS-A - 70% 70% 26.6 1.1 
pCMS-A 18% 52% 70% 29.7 2.1 
 
The chemical structure of the potent analgesic U50 contains a tertiary amine functionality (see 
Figure 2). To remove any salts that might interfere with the ionic interaction between CMS 
nanocarrier and U50, it was transferred into its respective base by basic precipitation with 
aqueous ammonia (see experimental). The free base of U50 was then used for encapsulation 
experiments into different CMS-nanocarrier types via the film uptake method. In this 
procedure, a film was prepared by adding stock solution of the guest molecule in an organic 
solvent into a vial, followed by subsequent evaporation. Then a nanocarrier solution was added 
on top of the film and the mixture stirred for 22 h. Excess guest was removed via filtration. 
The concentration of U50 in solution was then determined via HPLC, the loading capacities 
(LC) and encapsulation efficiencies (EE) are plotted in Figure 2. While the LC describes the 
mass ratio between encapsulated guest (wguest) and polymer (wpolymer, Equation 1), the EE 
relates the amount of the guest that has been encapsulated (wguest) to the amount of drug in the 





The results indicated that all tested carriers increased the solubility of the U50 free base by at 
least a factor of ten. Furthermore, comparing the two amide-based carriers, it becomes evident 
that attaching an additional anchoring point is beneficial for the loading of U50. At a feed of 
16%, the encapsulation efficiencies are rather high (between 60 and 90%), which indicates that 
the loading in the nanocarriers had not reached its saturation. This is in accordance with the 
data at 48 wt% of drug in the feed. The loading of all nanocarriers increased when the feed was 
raised from 16 to 48 wt%. Especially the pCMS nanotransporters showed a trend towards 
higher loading. These data indicate that the ester-bond was beneficial for the solubilization of 
the hydrophobic U50 free base and the additional binding patch increased the loading even 
further. 
 
Figure 2. Loading capacities (LC) as well as encapsulation efficiencies (EE) of U50 in the 
different carrier architectures. Error bars represent SD, n=3. 
3.2. pH-dependent size and ζ-potential 
In contrast to the neutral unfunctionalized CMS nanotransporters, the additional binding site 
can bear a charge due to the deprotonation of the acid group. To determine the pH-dependent 
behavior, the functionalized particles were dissolved in 1 mM NaOH (pH≈11) and titrated with 
1 M HCl. Both, hydrodynamic radius and ζ-potential were determined at different pH values 
(Figure 3). Furthermore, the apparent pKa (pKapp) of the functional group was determined. As 
expected, the pCMS-E exhibits a neutral ζ-potential at a pH below 4. At higher pH values, 
between 4 and 7, the carboxylic acid of the functional group is gradually deprotonated, which 
results in a negative surface-charge of the particle at a basic pH. The apparent pKapp of this 
nanocarrier is determined to be at 5.4. At higher pH values, the nanocarriers are in a charged 
state, resulting in separate, single particles of a hydrodynamic radius of around 10 nm, which 




form aggregates of 10 to 50 nm due to the lack of electrostatic repulsion. pCMS-A shows a 
very similar behavior regarding pH dependence. The particles are negatively charged at pH-
values above the pKapp and neutral below. In the same way, the particles aggregate in neutral 
state and deaggregate when deprotonated. One significant difference between the systems is 
the pKapp. It was higher in the case of pCMS-E than in the case of pCMS (4.4). The second 
difference is the presence of a second protonation step at a pKapp of 9.6, which indicated some 
unreacted free amines at the hPG amine core. Accordingly, the nanoparticle was not neutral at 
a pH below the pKapp, but had a slightly positive charge. 
 
Figure 3. pH-dependent hydrodynamic radii and zeta potential of the functionalized, ester-
based (left) and amide-based (right) carrier measurements were started at a conc. of 1 g L-1. See 
experimental section for more details. 
3.3. Release kinetics of U50 from different nanocarriers 
After having estimated the surplus value of the patch moieties regarding loading capacity, its 
role for a retention of U50 by the nanocarrier was determined. To measure this, a dialysis-based 
setup was used. A Pur-A-Lyzer dialysis container filled with donor solution was placed inside 
a reaction tube filled with 20 mL receptor medium. Then, samples were taken at different time 
points and the concentration determined via UV/Vis spectrometry. A simplified version (see 
Equations S1 and S2) of the theoretical model published earlier was used to fit the obtained 
data.[31] The fitting functions are plotted together with the original data in Figure 4, 5 and S3. 
In Figure 4 the release of U50 from either of the four nanocarrier architectures or as a mesylate 
salt is depicted. The data indicate that, as expected, the release without the presence of any 
carrier (Figure 4 left and right, black curve) was the fastest. Compared to that, the release from 
CMS-A only seemed to feature a weak retention effect, as the blue curve (Figure 4, right) did 
not differ from the black one very strongly and the error bars partially overlapped. The curves 




time points of only a few hours. While the ester-based carrier without binding patch (Figure 4 
left, blue curve) showed some retaining behavior, the retention was increased by the binding 
patch (Figure 4 left, green curve). The highest effect was found for the carrier pCMS-A. Here 
the binding patch affects the affinity of U50 to the nanoparticle the most.   
 
Figure 4. Release kinetics of U50 from functionalized and non-functionalized ester-based 
(left) and amide-based (right) nanocarriers at pH 7.4 (error bars represent SD, n=3). 
As already shown in Figure 3, the binding patch caused the nanocarrier to exhibit a pH-
dependent ζ-potential. To examine the influence of this effect on the release rate, the release 
experiment was repeated under various conditions. Along with the systemic pH, release studies 
from the nanocarrier architectures were performed at pH 5.5 (see Figure 5), which lay in the 
range of inflamed tissue. [44,46,47] Without any carrier (black and blue curves, Figure 5, left and 
right) there was no difference between pH 7.4 and 5.5. On the left, release without the presence 
of a nanocarrier is compared to the drug loaded into pCMS-E, on the right to pCMS-A. In this 
experiment, pCMS-A exhibited a retention effect at pH 7.4, but with an even lower pH of 5.5 
this effect persisted within the range of error. In contrast, pCMS-E (left, green and orange 
curves) shows pH dependent behavior. The release at pH 7.4 was slower than at pH 5.5, without 
the overlap of the error bars at the data points of 1 h, 4 h, and 8 h. This indicates that protonation 
of the nanocarriers reduced the affinity towards the U50 and facilitated an enhanced release. 
To achieve a better understanding of why of two chemically similar carriers only one exhibited 
a pH-responsive release, we have to take a closer look at Figure 3. From these graphs, it 
becomes evident that pCMS-E has a ζ-potential of -38 mV at a pH of 7.4 and this changes to -
19 mV at a pH of 5.5. In contrast, the ζ-potential of pCMS-A is around -32 mV at systemic pH 




compared to 19 mV (pCMS-E) is reflected in the binding affinity and indicates the importance 
of electrostatic binding in this system. 
 
Figure 5. Release kinetics of U50 from the functionalized ester-based (left) and amide-based 
(right) nanocarriers (error bars represent SD, n=3). 
As electrostatic interactions play an important role in this setup, it was elucidated if other 
parameters than pH interfere with these interactions. The two parameters that were chosen for 
this experiment were physiological salt concentration and the usage of the mesylate of U50 co-
dissolved with the nanocarriers instead of the free base encapsulated into them. The results of 
these experiments are depicted in Figure S3. On the left, the release kinetics of U50 mesylate 
salt without a carrier are compared with the ones of the free base encapsulated into pCMS-E 
and the mixture of mesylate salt and pCMS-E. As already shown, the encapsulated drug was 
retained by the nanocarrier and its release rate lowered. No different behavior was found for 
the sample of co-dissolved U50 mesylate and pCMS-E within the range of error. This result 
indicates that the mesylate counterions did not disturb the attractive interactions in a 
measurable way. 
The diagram on the right side of Figure S3 depicts the release behavior of U50 as a free drug 
in the presence of a NaCl concentration similar to the physiological one and encapsulated into 
pCMS-E with and without physiological salt. As shown already in Figure 4, pCMS-E retained 
the drug within the dialysis bag and lowered the release rate. The data indicate that in the 
presence of NaCl in physiological concentration, the release behavior was not altered. Thus, at 
this concentration, NaCl did not have a release-promoting effect. 
Using the fitting functions, the effectiveness of the different carriers over the course of time 




released U50 from a nanocarrier to the respective amount in the control experiment. The results 
are plotted in Fig. S5 and indicate that in most carriers under various conditions, the observed 
effect lasts in the range of 4 to 12 h, which is in the necessary range for the animal experiments. 
Furthermore, the fitting functions were used to extract the RT50-value (see SI). This value is 
the necessary time for 50% of the drug to enter the acceptor compartment (see also Eqation 
S5), which reduces a release experiment to one single value. The RT50 was calculated for all 
carriers and conditions investigated and plotted in Fig. S6, which nicely summarizes all carriers 
and conditions investigated in the release studies. This comparison indicates a low value for 
release experiments without carrier (1-1.5 h), while those with unfunctionalized nanocarriers 
(CMS-A and CMS-E) exhibited a value around 2 h. The usage of patch nanocarriers (pCMS) 
however led to much higher RT50 values (3-4 h), because of these nanocarriers’ retention. The 
only exception to this was pCMS-E at a pH 5.5, which featured an RT50 similar to the 
unfunctionalized carriers. This indicates once more that the beneficial properties of the 
additional functionalization were lost due to the lowered pH and thus enhanced release under 
these conditions was facilitated. For this reason, we chose pCMS-E to be the nanocarrier to be 
tested in vivo in the inflammatory pain model. 
3.4. Effects of intravenous U50, U50+CMS-E, and U50+pCMS-E on inflammatory 
pain 
Four days after induction of unilateral hindpaw inflammation, rats developed mechanical 
hyperalgesia (reduced paw pressure threshold, PPT) in inflamed compared to contralateral, 
non-inflamed paws (Figure 6). Intravenous injection of U50 (1-10 mg kg-1), U50+CMS-E and 
U50+pCMS-E (5-50 mg kg-1 polymer, and 1-10 mg kg-1 U50) significantly elevated PPT in 
inflamed paws compared to control treatment (empty CMS-E or pCMS-E; 50 mg kg-1, i.e., 
equivalent amount of carrier containing 10 mg kg-1 U50). The analgesic effects peaked at 10 
min and, in case of the highest, most effective dose, remained significantly increased until 45-
60 min following injection (Figure 6, left panel). At the two highest doses, all agonists 
significantly increased PPT also in contralateral, non-inflamed paws with the peak effect at 10-
15 min, and returned to baseline levels at 30-60 min (Figure 6, right panel). Control empty 





Figure 6. Analgesic effects after intravenous injection of U50 (A), U50+CMS-E (B) and 
U50+pCMS-E (C) in rats with unilateral hind paw inflammation. The effects on mechanical 
pain thresholds in inflamed (left panel) and contralateral, non-inflamed (right panel) hind paws 
were measured using the paw pressure test before (baseline) and 10-60 min after injection, at 
4 days following induction of inflammation. In B and C, the doses given in brackets represent 
the U50 equivalent doses. To reduce animal numbers, one control group was used for all 
agonists, and it was treated with empty CMS-E (4 rats) or pCMS-E (4 rats) (50 mg kg-1). #P < 
0.05 vs. contralateral, non-inflamed paws, Wilcoxon test. *P < 0.05, **P < 0.01, ***P < 0.001 
vs. control; two-way repeated measures ANOVA and Bonferroni test. Data are expressed as 
means ± SEM; n = 8 rats per group. 
 
As evaluated by the area under the curve (AUC), the analgesic effect of U50+pCMS-E in the 




and non-inflamed paws (Figure 7). Additionally, both U50+CMS-E and U50+pCMS-E (in the 
two highest doses), but not U50, appeared to produce slight sedation-type behaviour (up to 30 
min after injection). The sedative behaviour and analgesic effects in non-inflamed paws suggest 
that U50 derived from the carriers could cross the BBB and act centrally. However, the 
prolonged and enhanced analgesia indicates the retarded release of U50 from pCMS-E.  
 
Figure 7. Analgesic effects after intravenous injection of U50, U50+CMS-E, and U50+pCMS-
E in inflamed (A) and contralateral, non-inflamed paws (B) in rats with unilateral hind paw 
inflammation, expressed as area under the curve (AUC). The AUC values were calculated from 
the data depicted in Figure 7: The doses represent the U50 equivalent doses; the polymer doses 
were 5-50 mg kg-1, respectively. The control group was treated with empty CMS-E (4 rats) or 
pCMS-E (4 rats) (50 mg kg-1). *P < 0.05; Kruskal-Wallis one-way ANOVA and Dunn’s test. 
Data are expressed as means ± SEM; n = 8 rats per group. 
4. Conclusion 
In this study, we presented the synthesis of two novel pCMS nanocarriers, pCMS-E and pCMS-
A, that were able to encapsulate the analgesic drug U50 in high percentages. In subsequent 
release experiments, both pCMS exhibited a retarded release of U50, pCMS-E in a slightly pH-
dependent manner. U50+pCMS-E was then selected to be tested in comparison to U50+CMS-
E and U50 in vivo in the clinically relevant inflammatory pain model. Surprisingly, both U50-
containing nanocarriers exerted analgesia in both inflamed and non-inflamed tissue, suggesting 
U50 systemic absorption and action in the central nervous system. Along with these effects, a 
prolonged and enhanced analgesia was observed when U50 was incorporated into the pCMS-
E nanocarrier. These results suggest an increased blood circulation time of U50 carried by this 




for the longer-lasting pain relieve. Future studies will be required to restrict the delivery of U50 
to peripherally inflamed tissue and to further prevent unspecific leaching. 
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Figure S1. Chemical structure (box) and 1H-NMR spectrum of pCMS-A in methanol. 
 
















Figure S2. Chemical structure (box) and 1H-NMR spectrum of pCMS-E in methanol. 
 
2. Release Kinetics of U50 from pCMS-E under various conditions 
 
Figure S3. Release kinetics of U50 from pCMS-E under various conditions. Left: U50 without 
carrier (black), U50 encapsulated into pCMS-E (blue), and U50 co-dissolved as mesylate salt 
with pCMS-E (green). Right: U50,488 without carrier (black) and with 140 mM NaCl (blue), 
U50 encapsulated into pCMS-E with 140 mM NaCl (orange) and without (green), n=3. 
 
3. Fitting functions for modelling 
Equal to a previously developed mathematical model,[1] fitting Equation S1 describes the 
fraction of drug in the receptor medium. It was used to calibrate the system without carrier. 
Then the model was expanded by the presence and influence of the nanocarrier expressed by 

























the parameters s3, as well as the diffusion rates from the nanocarrier into the donor solution and 
back (rNI and rIN), which yielded Equation S2. 
 
Φ0(𝑡) = 𝑟𝐼𝑀𝑟𝑀𝐼 𝑠1 − 𝑠2 + 𝑠2𝑒𝑠1𝑡 − 𝑠1𝑒𝑠2𝑡𝑠1𝑠2(𝑠1 − 𝑠2)  (S1) Φ0(𝑡) = 𝑟𝐼𝑀𝑟𝑀𝐼 [ 𝑒𝑠1𝑡(𝑟𝑁𝐼 + 𝑠1Φ𝐼0)𝑠1(𝑠1 − 𝑠2)(𝑠1 − 𝑠3) + 𝑒𝑠2𝑡(𝑟𝑁𝐼 + 𝑠2Φ𝐼0)𝑠2(𝑠2 − 𝑠1)(𝑠2 − 𝑠3)+ 𝑒𝑠3𝑡(𝑟𝑁𝐼 + 𝑠3Φ𝐼0)𝑠3(𝑠3 − 𝑠1)(𝑠3 − 𝑠2) − 𝑟𝑁𝐼𝑠1𝑠2𝑠3)] (S2) 
 
4. Normalised Release (NR) 
The impact of the retention effect changes over time. To quantify the influence over the course 
of time, it was normalised. This was done by relating it to its control experiment which was 
conducted under the same conditions but without nanocarrier (see exemplarily Equation S3). 𝑁𝑅U50@CMS−A,pH 7.4(t) = Φ𝑂;𝑈50,𝑝𝐻 7.4 (𝑡)Φ𝑂;U50@CMS−A,pH 7.4 (𝑡) (S3) 




Figure S4. Normalized release of all investigated nanocarriers. The released amount without 
carrier was up to 2.2-fold higher than the one from the respective nanocarrier. The effect 
lasted between 4 and 12 hours. 
5. Release time 50 (RT50) 
The release time 50 is the time necessary for 50% of the U50 to reach the acceptor medium. 
Thus, it is used to reduce the measured retention to a single value. It was numerically 
determined based on the fitting functions obtained by the modelling of the measured data (see 
Section 3) and by employing Equation S5. Φ𝑂(t = 𝑅𝑇50) = 0.5 (S5) 
 




Figure S5. RT50 values for all investigated nanocarriers and the respective controls. The 
experiments were either carried out at pH 5.5 of 7.4, with (blue bars) or without a nanocarrier 
(grey bars) and with or without physiological salt concentration. The nanocarriers were either 
ester-based (light blue bars) or amide-based (dark blue bars) and optionally had an anchor 
group (orange border).  
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In dieser Arbeit wurde das Design zwei verschiedener Nanocarrierarchitekturen 
realisiert mit dem Ziel, entweder niedermolekulare, hydrophobe Wirkstoffe zu 
verkapseln und deren Penetration in die Haut zu erhöhen, oder ein kationisches 
Analgesikum zielgerichtet in entzündetes Gewebe zu transportieren.  
Im ersten Teil wurde von der bisher genutzten, Amid-basierten Synthesestrategie, zu 
einer Ester-basierten gewechselt, um erstens den potentiell toxischen Kernbaustein 
hPG-NH2 zu vermeiden und zweitens, um die Bioabbaubarkeit zu verbessern. Des 
Weiteren wurden langkettige α-ω-Dicarbonsäuren mit verschiedenen Kettenlängen 
als Bausteine für die innere, lipophile Schale verwendet, und der Einfluss der Struktur 
dieses Bausteins auf Beladungskapazität, Schmelztemperatur und Abbau- bzw. 
Freisetzungskinetik untersucht. Während die Schmelztemperatur mit der Kettenlänge 
der inneren Schale stieg, sank sie mit zusätzlicher Verzweigung. Eine Amidgruppe 
hatte ebenfalls einen steigernden Effekt auf die Schmelztemperatur. Bei der 
Verkapselung des relativ rigiden Wirkstoffs Dexamethason (DXM) wurde kein starker 
Zusammenhang zwischen den verschiedenen Strukturen der inneren Schale und der 
Beladungskapazität beobachtet. Im Gegensatz dazu ergab sich bei dem eher flexiblen 
Makrozyklus Tacrolimus ein Maximum der Beladungskapazität bei einer mittleren 
Kettenlänge von C15. Es konnte ferner gezeigt werden, dass unbeladene CMS 
nanocarrier von Lipasen innerhalb von 14 Tagen zu mehr als 70% abgebaut werden 
können, und dass DXM-beladene CMS Nanotransporter durch den Abbau ihre Ladung 
freisetzen.  
Des Weiteren wurden einige der synthetisierten Systeme bezüglich ihrer Toxizität und 
Penetrationsverstärkung hin untersucht. Während sich CMS-E18 und vor allem der 
Doppelschalebaustein C18-PEG350, vermutlich aufgrund seiner Interaktion mit 
Zellmembranen als relativ toxisch erwies, konnte CMS-E15 als besonders 
biokompatibel identifiziert werden. Nachfolgende Tests mit Nilrot-beladenen CMS 
Nanocarriern auf exzidierter Humanhaut zeigten, dass Kettenlänge und Art der 
chemischen Bindung zum Kern keinen großen Einfluss auf die 
Penetrationsverstärkung hatten, alle untersuchten Architekturen jedoch einer 
Basiscreme überlegen waren. Untersuchungen mit DXM-beladenen CMS-E15 auf 





gleichkonzentrierten Creme eine höhere entzündungshemmende Wirkung entfalten 
konnte. 
Weiterführende Studien auf Mundschleimhaut bestätigten die penetrations-
verstärkende Wirkung von CMS Nanocarriern. Verkapseltes, spingelabeltes DXM 
konnte hier leichter in das Gewebe eindringen, als solches, das in einer Creme 
formuliert war. Außerdem drangen fluoreszenzmarkierte Nanocarrier verstärkt in die 
viable Epidermis ein, als dass auf normaler Haut gemessen wurde.  
Der zweite Teil der Arbeit befasste sich mit der Aufnahme und der kontrollierten 
Freisetzung des kationischen aromatischen Analgesikums U 50,488 (U50). 
Zusätzliche Ankergruppen wurden am Kern befestigt, sodass U50 über ionische und 
aromatische Wechselwirkungen sowie Wasserstoffbrückenbindungen stärker an die 
CMS Nanocarrier gebunden wurde. Die mit Bindungspatches funktionalisierten CMS 
(pCMS) wurden hinsichtlich ihres pKapp charakterisiert, welcher wichtig für die 
Freisetzung ist. Bei der Bestimmung der Beladungskapazität mit U50 (freie Base) 
zeigten sich die pCMS den unfunktionalisierten Nanopartikeln überlegen. Dies wurde 
auch durch die anschließenden Freisetzungsstudien bestätigt. Während U50 aus 
CMS ohne Ankermolekül relativ schnell herausdiffundierte, war die Freisetzung aus 
pCMS wesentlich langsamer. Auch spielte es keine Rolle, ob Kochsalz in 
physiologischen Konzentrationen vorhanden war oder ob U50 als freie Base 
verkapselt oder in gleicher Konzentration als Methylsulfonat hinzugegeben wurde. Als 
einzige Architektur zeigte pCMS-E einen Unterschied im Freisetzungsverhalten bei 
pH 5.5 und pH 7.4. Dieses System wurde daraufhin in einem in vivo Rattenmodell 
getestet. Auch wenn hier kein erhöhter Transport ins entzündeten Gewebe 
nachgewiesen worden ist, zeigte sich eine verzögerte Freisetzung aus dem 
Nanocarrier, welche sich durch eine verstärkte und länger andauernde Analgesie 
ausdrückte.    




5 Summary and Conclusion 
This work explored the possibilities to design CMS nanocarriers for two different types 
of problems, the encapsulation of small hydrophobic drugs and subsequent transport 
into skin or the retention and targeted release of a cationic analgesic. The aim of the 
first part was to design a set of nanocarriers for the encapsulation and penetration 
enhancement of these drugs and thereby fulfilling the following criteria: Ease of 
synthesis, non-toxic products and building blocks, good loading capacity, 
degradability, and degradation-based release and high penetration enhancement.  
To simplify the synthesis, the dendritic building block, which poses the focal point in 
the nanocarrier architecture, was exchanged. Instead of hPG-NH2, unfunctionalized 
hPG was used. This change in the synthesis process had two main impacts. First, this 
strategy spared three synthetic steps thereby making the procedure less time 
consuming. Secondly, the potentially toxic building block hPG-NH2 was avoided and 
thus could not harm the organism post-application as a degradation product. This 
change was the next step in decreasing the number of amine groups in the core and 
thus the toxicity ranging from PEI over hPG-NH2 to hPG.[83,85] The inner shell’s 
building block was varied in length to study the impact on encapsulation, melting 
temperature and penetration enhancement. Aliphatic diacids with a number of carbon 
atoms between 12 and 19 as well as a branched version of the one with 18 carbon 
atoms were used as inner shell building blocks. While, in previous studies, the length 
of the inner shell had already been altered with bigger steps (six C-atoms),[83] here 
the focus shifted more onto details and other structural features. The different systems 
showed an increase of the melting temperature (Tm), of the inner shell with increasing 
chain length. And while an amide bond in the structure significantly increased the Tm, 
the introduction of side arms led to its decrease. While the rigid molecule 
dexamethasone (DXM) showed no apparent correlation between chain length and 
loading capacity, the situation was different for the bulkier tacrolimus. Here, an 
optimum was found for a C15 inner shell. Interestingly, while the additional branching 
did not lead to results different from the linear ester-based architecture, the loading 
capacity plummeted when an amide-based nanocarrier was used.  
All examined nanocarriers were degraded by a lipase to a degree of more than 70% 
in two weeks, which was similar to other ester-based nanotransporters.[124,125] The 




degradation of DXM-loaded CMS nanotransporters led to the loss of their function as 
a solubilizer, more than 80% of the loading was released. Thus, the degradation can 
serve as a possible release mechanism.  
Various assays were carried out to determine toxicity. Of the investigated ester-based 
CMS architectures, CMS-E15 showed the least cytotoxicity. The others caused a 
decrease in cell viability, at least to some extent. Of the building blocks, the aliphatic 
diacids were only toxic after prolonged exposition, but of the PEG-conjugated diacids, 
cytotoxicity increased from C12 to C18, which was attributed to interaction with the 
cell membrane. The most toxic building block was C18-PEG350, also with regard to 
genotoxicity. The CMS-E18 nanocarrier, the product of this building block, also 
exhibited some ROS generation and genotoxicity. The overall least toxic, ester-based 
nanocarrier was CMS-E15, which was selected for in vivo testing and was nontoxic 
when applied to the skin of Sprague Dawley rats.   
After establishing the biocompatibility of the different candidates, the CMS 
nanocarriers were tested for skin penetration and penetration enhancement of several 
guest molecules on various skin models. Nile red-loaded and DXM-loaded CMS-
nanocarriers were used to study the penetration enhancement on excised human skin. 
All nanocarriers proved to be superior over a formulation with base cream (NR) or 
LAW cream (DXM), which was in accordance with previous results.[85] The 
nanotransporters showed no dependence on inner shell chain length or type of bond 
for attachment. CMS-E15 was then loaded with dexamethasone and applied on an 
inflammatory skin model which had an upregulated interleukin 8 (IL-8) and IL-1β 
expression as part of their inflammatory condition. The application of the DXM-loaded 
nanocarriers reduced the expression of both ILs more effectively than a LAW cream 
with equal DXM content. 
The CMS nanocarrier was not only tested for application on skin, but for oral mucosa 
as well. Here, biocompatibility was of even higher importance, because the constant 
flow of saliva eventually flushed the CMS nanocarriers into the GI tract if not taken up 
by the mucosa. Along the penetration experiment, toxicity of the CMS 
nanotransporters was determined for gingival epithelial cells and found to be only 
cytotoxic at very high concentrations. The penetration enhancement of PCA-labeled 
dexamethasone encapsulated in CMS-E15 and the penetration of ICC-labeled, amide 




based CMS nanocarriers (CMS-ICC) was measured on buccal and masticatory 
mucosa. While penetration of unloaded CMS-ICC nanocarriers was limited to the 
stratum corneum on skin,[122] a small fraction also penetrated more deeply into viable 
tissues, in masticatory slightly more than in buccal mucosa. Although the conditions 
were not identical, this result might have indicated a higher penetrability for oral 
mucosa compared to skin, which might be related to a difference in the structure of 
both tissues. For the penetration enhancement of spin-labeled DXM (DXM-PCA) by 
CMS-E15, similar results were found as in skin. Even after a washing step, which 
simulated the flow of saliva in the oral cavity, penetration enhancement of the labeled 
drug was found. The CMS nanotransporters enhanced the penetration of DXM-PCA 
more than a cream formulation, and buccal mucosa generally seemed more 
penetrable than masticatory mucosa for DXM-PCA. Additionally, X-band electron 
paramagnetic resonance spectroscopy revealed that the guest molecule left its 
vehicle. This observation was in accordance with previous observations,[122] which 
indicated that nanocarrier and guest molecule penetrated up to different depths. Taken 
together, these three studies describe a step-wise selection process at which out of 
six different initial candidates, one was selected by criteria like ease of synthesis, drug 
loading capacity, and biocompatibility. The nanocarrier with the best overall 
performance and thus most promising for future applications was CMS-E15.  
The aim of the second part of this work was to design a nanocarrier for the 
encapsulation and controlled release of the drug U 50,488H (U50), which is a strong 
analgesic for the post-operational pain treatment but elicits side effects when it crosses 
the blood brain barrier. A formulation into a nanocarrier can help to increase circulation 
time and facilitate targeted release. After surgery, the tissue is inflamed and thereby 
acidified and fenestrated. To use these conditions for the targeted release of U50, a 
nanocarrier was synthesized that offered the possibility to encapsulate U50 efficiently 
and release it in a pH-dependent manner. 
As basic architectures, CMS-E15 and CMS-A18, which were the most promising 
candidates in previous studies, were used and extended by an anchor moiety. It was 
needed, because there was no possibility to bind the drug covalently to the 
nanocarrier. For this task, N-Z-L-protected aspartic acid was utilized, because it 
offered the possibility for ionic interactions, π-π stacking, and hydrogen bonds to U50. 
Further, it was possible to employ the carboxylic acid groups for a pH-dependent 




release. While many approaches in literature used a hydrophobic segment that was 
ionized upon a pH change and thus,[126–128] a lipophilic guest is expelled, here, the 
opposite is the case. Ionic interactions are interrupted and thus the ionic drug can 
diffuse out of the nanocarrier.  
After synthesis, the pKapp of the carboxylic acid groups was determined to be in the 
physiological range (4.4 for pCMS-A and 5.4 for pCMS-E) and the loading capacity 
(LC) and encapsulation efficiency (EE) for U50 free base was measured. While the 
EE at 16 wt% feed already exceeded 10% for all nanocarriers (> 60% EE), the feed 
was increased to 48 wt%. Under these conditions, the LC of all nanoarchitectures 
could be increased, especially for the pCMS, which reached up to 28% (> 50% EE). 
Subsequently, the release kinetics were studied under various conditions to determine 
the influence of the additional functionalization and factors like pH, the encapsulation 
of the free base or the methylsulfonate salt, or the presence of physiological salt 
concentration. While the latter two had no influence on the release kinetics, the 
functionalization with the binding patch was beneficial for the retention of U50. In the 
case of pCMS-A, there was no difference in this effect at pH 5.5 and 7.4, but for 
pCMS-E, a pH dependence was found. For this reason, pCMS-E was selected for an 
in vivo study in rats. Here, formulations of U50 with and without pCMS-E were 
compared regarding prolonged analgesia and reduced side effects. While the latter 
one was not the case, the formulation with additional pCMS-E resulted in the 
enhancement and the extension of the analgesic effect, which might indicate a longer 
blood circulation time caused by the nanocarrier. In a previous prodrug approach, 
morphine covalently attached to hPG was tested under similar conditions and the 
absence of a systemic side effect reported.[61] Taken together, these two studies 
indicated that to optimize post-operational pain treatment, nanocarrier architectures 
ideally have a sufficiently high molecular weight for a prolonged blood circulation time 
and bind the analgesic tightly enough to prevent premature release. If possible, this 
should be realized in a DDS approach, to make the drug interchangeable. 
When first reported, the core-multishell nanocarrier was termed universal, because it 
was suitable for both hydrophilic and hydrophobic guest molecules in both aqueous 
and organic media. Subsequent studies confirmed that and reported the encapsulation 
of even inorganic nanoparticles and explored the fundamental effects, such as the 
aggregation of nanoparticles and guest molecules, which were also described 




theoretically. In a more application-focused approach, many nanocarriers were 
designed for a certain guest, e.g., copper ions, or target, for instance, the endosome. 
Ideally both can be achieved, namely, the identification of a promising architecture and 
further insight into fundamental effects.  
In this work, this was achieved. In the first part, it could be shown that there is an 
optimum chain length for the encapsulation tacrolimus and that the addition of one 
CH2 group to the aliphatic chain can alter the nanocarrier’s properties dramatically. 
There also was a dependence of cytotoxicity on the length of the hydrophobic part of 
the amphiphilic double shell, which altogether identified CMS-E15 as the most 
promising candidate. Addressing oral mucosa with CMS showed that this is an 
interesting field for DDS like CMS nanocarriers, because even more efficient 
penetration seems to be possible. 
In the more application-focused second part, the pH-dependent retention effect that 
was measured for the best candidate pCMS-E. Even though the encapsulation of 
hydrophilic guest molecules remains a greater challenge than the formulation of 
hydrophobic ones, this showed that it was possible even for rather small nanocarrier 
systems (diameter ~10 nm) to bind a water-soluble drug. Additionally, it could be 
proven that the chemistry used to attach the anchor moiety influenced the pKapp and 
thus is crucial for the application. Different anchor molecules could be employed to 
further fine-tune the pH of release and the retention effect proven in this study might 
be improved by increasing the nanocarrier’s sizes. One advantage of the DDS-
approach is that pCMS are a potential nanocarrier suitable for any aromatic, 
hydrophobic drug molecule that bears a positive charge, e.g. by an amino group.  
The past research conducted on CMS nanocarriers has shown that, starting from a 
universal nanocarrier, of which mainly fundamental effects have been studied, many 
subclasses and varieties have been realized to meet specific requirements. To be 
suitable for future applications, a universal nanocarrier will not be able to solve all the 
problems. It will be necessary to adapt the nanocarrier’s architecture to the 
requirements of drug and physiological condition. And to achieve that, a library of CMS 
nanocarriers is needed to study fundamental effects and to select a potential candidate 
for an application. It is important to design new architectures, because the human 









Based on the current findings, the following projects could yield interesting 
nanocarriers or approaches for applications: 
Size has a substantial influence on the distribution of a DDS in the body, drug loading 
capacity, and release kinetics. Construction of a nanocarrier with a bigger and more 
accessible core can improve drug loading and limit diffusion out of the DDS. To obtain 
a low-PDI core, tecto-dendrimers, which are core-shell constructs of dendrimers, can 
be used. They are defined and are known to transport guest molecules, so the 
nanocarrier will not only have the shell, but also the core volume to encapsulate drug 
molecules.  
As the pCMS showed the promising ability to encapsulate U50, other amine-containing 
hydrophobic drugs might also benefit from this tailored functionalization. Tofacitinib is 
currently in clinical trials for psoriasis treatment. Encapsulation in pCMS could 
increase skin penetration and thus the effect of this drug. Also, a pCMS-based 
formulation could improve the efficacy of micro-needle vaccinations.  
In applications to the oral cavity, the flux of saliva usually poses a problem. A solution 
could be to employ a two-component system. CMS nanocarriers penetrate mucus 
relatively quickly and enter the stratum corneum, but are partially washed away by the 
flow of saliva. To prevent this, a mucus-binding macrogel could be used to formulate 
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